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Summary 
Perivascular adipose tissue (PVAT) surrounds most systemic blood vessels and is a well-known 
regulator of blood vessel reactivity. In hypertension, deregulated PVAT properties contribute to the 
impairment of the functionality of the adjacent blood vessel. A question that remains to be 
addressed is which signaling pathways are involved in the deregulation of PVAT function in these 
pathophysiological conditions. One of the central cellular regulators is the mammalian target of 
rapamycin (mTOR) acting as a sensor for environmental conditions. mTOR exists in two functional 
distinct complexes, mTORC1 and mTORC2. The rapamycin-insensitive companion of TOR (RICTOR) is 
a component of mTORC2 and essential for mTORC2 activity. Focusing on the role of mTORC2 in the 
cardiovascular system, our laboratory discovered mTORC2 as a potential regulator of PVAT function. 
Using adipocyte protein 2 (aP2) gene promoter-driven CRE-recombinase expressed in adipocytes, 
deletion of Rictor in mice (RictoraP2KO) identified mTORC2 in PVAT as a novel regulator of vascular 
reactivity primarily by controlling pro-inflammatory molecule expression such as inducible nitric 
oxide synthase (iNOS). Inhibition of iNOS restored vascular reactivity indicating a significant 
contribution of iNOS to the impaired vascular reactivity.  
The present study aimed to assess whether mTORC2 contributes to blood pressure regulation and to 
identify signaling pathways involved using RictoraP2KO mice.  
 
Verification of Rictor deletion in RictoraP2KO mice revealed reduced mRNA expression of Rictor in 
PVAT, in epididymal fat (EFAT), in adipocytes isolated from EFAT, in the brain regions suprachiasmatic 
nucleus (SCN) and cortex, while in the aortic tissue, the kidney, the heart, the stromal vascular 
fraction, monocytes and T cells the expression of Rictor was similar in RictoraP2KO and control mice. 
Cross sections of thoracic PVAT uncovered a higher adipocyte cell density of RictoraP2KO mice. Analysis 
of daily insulin fluctuations has shown an overall increase of the 24 hour insulin plasma levels in 
Rictor
aP2KO mice. To investigate whether the changes in vascular reactivity and morphology of 
Rictor
aP2KO mice translate into higher blood pressure, hemodynamic parameters were recorded using 
radiotelemetry in free moving mice. The 24 hour average of the mean (MAP; P<0.05) and diastolic 
arterial pressure (DAP; P<0.05) was slightly increased in RictoraP2KO mice compared with controls. 
Separate analysis of the 12 hour light and 12 hour dark periods revealed time-of-day dependent 
effects of RICTOR/mTORC2 on blood pressure regulation. During the dark period the physiological 
decline in MAP was strongly impaired in RictoraP2KO mice. Similarly, heart rate (HR; P<0.01) and 
locomotor activity parameters were elevated and remained high during the progression of the dark 
period in these mice. Inhibition of iNOS using subcutaneously implanted mini pumps releasing 
1400W did not lower blood pressure in RictoraP2KO mice. To evaluate possible hypertrophic changes, 
we assessed the morphology of the heart. Mean absolute heart weights in RictoraP2KO mice were 
Summary 
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higher compared with controls, while the mean relative to body heart weight was not changed. 
Interventricular septal and right ventricular free wall thickness (P=0.08 and P=0.09, respectively) 
tended to be increased and cardiomyocytes were mild hypertrophic (P<0.01) in RictoraP2KO mice. 
mRNA expression of the cardiac hypertrophic biomarkers atrial natriuretic peptide (Anp; P<0.05) and 
brain NP (Bnp; P=0.11) was reduced in these mice and mRNA transcriptional levels of the NP 
receptors Npr2 (P<0.05) and Npr3 (P<0.05) were decreased in adipocytes isolated from EFAT. A 
similar expression pattern was detected in PVAT. 
To identify connections of the physiological changes observed in RictoraP2KO mice to the mTORC2 
network, a micro array analysis of the expressed PVAT genome was performed. 68 genes were 
differentially expressed (P<0.05 and fold change > 1.5) in PVAT of RictoraP2KO mice compared with 
controls. Subsequent gene ontology analysis revealed the circadian rhythm regulated by clock genes 
as the most affected pathway. Well-designed clock gene expression controls daytime-dependent 
behaviors and mammalian physiology. Mutations and deletions of clock genes have been associated 
with changes in blood pressure and locomotor activity. In this context, it was essential to clarify the 
impact of Rictor deletion on peripheral clock gene expression in PVAT during a 24 hour cycle. mRNA 
expression level of Period 1 (Per1), Circadian locomotor output cycles kaput (Clock), Cryptochrom 1 
(Cry1) and Retinoic-acid related orphan receptor alpha (Rorα) were reduced specifically during the 
light period, while Period 2 (Per 2) exhibited a phase shift at the transition from the light to the dark 
period in PVAT of RictoraP2KO mice compared with controls. Intriguingly, we found Rictor mRNA 
expression to be time-of-day dependent in control mice with highest levels during light period. 
Similar, mTORC2 activity was daytime dependent as the phosphorylation of AKT at Ser473 was higher 
at the beginning of the light period. In addition to the reduced Rictor mRNA expression, we found a 
17 % reduction in brain size in RictoraP2KO mice compared with controls. Therefore, a potential impact 
of Rictor deletion in the brain cannot be excluded, particularly in the SCN where the biological master 
clock is located, that might explain the observed changes in daily fluctuations of blood pressure and 
locomotor activity. In the SCN, 24 hour mRNA expression of core clock genes was similar between 
groups.  
In conclusion, the data of the present study show for the first time the importance of RICTOR and/or 
mTORC2 in the brain and adipocytes to regulate daily fluctuating physiological processes such as 
blood pressure and locomotor activity. This function of RICTOR is likely located downstream or 
independent of the molecular clock mechanisms in the SCN, and may involve the hormones NPs and 
insulin. In PVAT, affected clock genes might contribute to the increased pro-inflammatory molecule 
expression. Future studies to elucidate these complex interactions in the adipocyte-brain axis may 
lead to the identification of novel strategies to develop effective treatments against hypertension. 
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Zusammenfassung 
Perivaskuläres Fettgewebe (PVAT) umschließt die meisten systemischen Blutgefäße und reguliert ihre 
Reaktivität. Bei Bluthochdruck und Fettleibigkeit verändern sich die Eigenschaften des PVATs und 
ebenso die Reaktivität der umschlossenen Blutgefäße. Trotz intensiver Forschung sind Signalwege im 
PVAT unter physiologischen und pathophysiologischen Bedingungen wenig charakterisiert.  
Von grundlegender Bedeutung für die Integration von Signalen auf zellulärer Ebene ist das Protein 
„mammalian target of rapamycin“ (mTOR). mTOR ist eine evolutionär konservierte Kinase und 
integriert die durch Wachstumsfaktoren und Nährstoffe generierten Signale auf zellulärer Ebene und 
reguliert das Zellwachstum. mTOR ist Bestandteil von zwei verschiedenen Proteinkomplexen: 
Komplex 1 (mTORC1) und Komplex 2 (mTORC2). Ein für die Aktivität von mTORC2 essentielles 
Adapterprotein ist „rapamycin-insensitive companion of TOR“ (RICTOR). Um die Rolle von mTORC2 in 
PVAT näher zu charakterisieren, haben wir in unserem Labor eine spezifische Mausmutante 
verwendet, in der das Gen Rictor nicht funktionsfähig exprimiert wird. Der Gen Knockout wurde 
unter Verwendung des adipocyte protein 2 (aP2)-Promoter/CRE-Rekombinase Systems generiert.  
Unter Verwendung dieses Mausmodels (RictoraP2KO) konnte unser Labor kürzlich zeigen, dass 
mTORC2 zur Regulierung von PVAT Eigenschaften unter physiologischen Bedingungen beiträgt. In 
Rictor
aP2KO Mäusen, ist die mTORC2 Aktivität im PVAT reduziert. Dies führt zu einer erhöhten 
Expression von pro-inflammatorischen Molekülen (tumor necrosis factor alpha, interleukin 6 und 
inducible nitric oxide synthase/iNOS). Durch spezifische Inhibierung von iNOS konnte die Reaktivität 
der thorakalen Aorta in RictoraP2KO Mäusen wieder hergestellt werden. Dies deutet auf einen 
signifikanten Beitrag von iNOS zur veränderten vaskulären Reaktivität der thorakalen Aorta hin. 
Ziel dieser Studie war es herauszufinden, ob mTORC2 nicht nur zur vaskulären Reaktivität beiträgt, 
sondern auch Einfluss auf die Regulierung des Blutdrucks in Mäusen hat. Des Weiteren wurde die 
Genexpression in PVAT von RictoraP2KO im Vergleich zu Kontrollmäusen näher analysiert.  
Deletion von Rictor in RictoraP2KO  Mäusen führte zur Reduktion der Genexpression von Rictor im 
PVAT, epididymalem Fettgewebe (EFAT), in von EFAT isolierten Adipozyten sowie den 
Gehirnregionen suprachiasmatischer Nukleus (SCN) und Kortex. In der Aorta, der Niere, dem Herz, 
der „stromal vascular fraction“, Monozyten und T Zellen konnte keine veränderte Rictor Expression in 
Rictor
aP2KO festgestellt werden. Weiterführende histologische Untersuchungen ergaben zudem eine 
erhöhte Zelldichte des thorakalen PVATs in RictoraP2KO Mäusen. Eine Analyse der Insulin-
Konzentration im Blut über einen Zeitraum von 24 Stunden, ergab einen erhöhten Insulin-Spiegel in 
Rictor
aP2KO Mäusen. 
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Morphologische Veränderungen des PVATs bzw. dessen Einfluss auf die vaskuläre Reaktivität deuten 
auf mögliche Veränderungen im Blutdruck hin. Um dieser Frage nachzugehen, haben wir unter 
Verwendung von Radiotelemetrie in sich frei bewegenden RictoraP2KO und Kontrollmäusen Blutdruck 
sowie ihre Bewegungsaktivität gemessen. Für den mittleren arteriellen Blutdruck (MAP; P<0.05) als 
auch für den diastolische Blutdruck (DAP; P<0.05) wurden erhöhte Durchschnittswerte über 24 
Stunden in den RictoraP2KO Mäusen gemessen. Eine separate Analyse der 12 Stunden Tag- und 12 
Stunden Nachtphase ergab einen tageszeitenabhängigen Effekt von RICTOR/mTORC2 auf die 
Blutdruckregulation. Im Gegensatz zu den Kontrollmäusen, konnte kaum ein physiologischer 
Rückgang des MAP in RictoraP2KO Mäusen während der 12 Stunden Nachtphase beobachtet werden. 
Auch die Herzrate (HR; P<0.01) und die Bewegungsaktivität waren erhöht und ihre physiologische 
Abnahme in der 12 Stunden Nachtphase stark verringert in RictoraP2KO Mäusen. In vivo Infusion von 
1400W, einem iNOS spezifischen Inhibitor, durch subkutan implantierte osmotische Minipumpen 
konnte nicht den Blutdruck in RictoraP2KO Mäusen normalisieren. Morphologische Untersuchungen 
des Herzens ergaben leicht hypertrophe Kardiomyozyten in RictoraP2KO Mäusen sowie eine 
verringerte Expression der natriuretischen Peptide (NP) Anp (P<0.05) und Bnp (P=0.11). Des Weiteren 
war die Genexpression der NP Rezeptoren Npr2 (P<0.05) und Npr3 (P<0.05) in Adipozyten, welche 
vom EFAT isoliert wurden, verringert. Im PVAT fand sich ein ähnliches mRNA Expressionsmuster. 
Um einen Zusammenhang zwischen Veränderungen im Blutdruck bzw. der Bewegungsaktivität in 
Rictor
aP2KO Mäusen mit der verringerten mTORC2 Aktivität zu untersuchen, haben wir die 
Genexpression im PVAT gemessen. Die Analyse ergab 68 signifikant veränderte Gene (P<0.05 und 
„fold change“ > 1.5) in RictoraP2KO  Mäusen im Vergleich zu den Kontrollmäusen. Eine vertiefende 
Genontologie-Analyse ergab, dass ein Großteil dieser Gene mit dem zirkadianem Rhythmus assoziiert 
ist. Veränderungen dieser sogenannten Uhren-Gene mit Hilfe von Mutationen, führen zu 
Veränderungen im Blutdruck, die mit der Bewegungsaktivität assoziiert waren. In RictoraP2KO  Mäusen, 
die Expressionsanalyse dieser Uhren-Gene auf mRNA Ebene im PVAT über 24 Stunden ergab 
Veränderungen in folgenden Genen: Period 1 (Per1), Circadian locomotor output cycles kaput (Clock), 
Cryptochrom 1 (Cry1) und Retinoic-acid related orphan receptor alpha (Rorα) zeigten in der 12 
Stunden Tagphase eine verringerte Expression, wohingegen Period 2 (Per2) eine Phasenverschiebung 
beim Übergang von der Tag- zur Nachtphase aufwies. Alle anderen Uhren-Gene wiesen keine 
Veränderung in ihrem Expressionsmuster auf. Interessanterweise war die Expression von Rictor im 
PVAT ebenfalls tageszeitenabhängig und zu Beginn der 12 Stunden Tagphase am Höchsten.  
Veränderungen des tageszeitenabhängigen Rhythmus im Blutdruck und der Aktivität in den 
Rictor
aP2KO Mäusen hat uns dazu veranlasst, den Einfluss der Deletion von Rictor im Gehirn näher zu 
analysieren. Eine wichtige Rolle in der tagezeitenabhängigen Regulierung des Blutdrucks spielt der 
suprachiasmatische Nukleus (SCN). Eine Analyse der Expression der Uhren-Gene im SCN über 24 
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Stunden ergab keine Unterschiede zwischen RictoraP2KO und Kontrollmäusen. Dies deutet darauf hin, 
dass RICTOR/mTORC2 nicht zur Regulierung der Expression der Uhren-Gene im SCN beitragen. 
Interessanterweise, ähnlich dem PVAT ist auch im SCN die Expression von Rictor 
tageszeitenabhängig. 
Zusammenfassend konnte in dieser Studie zum ersten Mal gezeigt werden, dass RICTOR und/oder 
mTORC2 in die Regulierung von Blutdruck und Bewegungsaktivität involviert sind. In RictoraP2KO 
Mäusen war nicht nur der Blutdruck erhöht, sondern auch sein physiologischer Rückgang während 
der 12 Stunden Nachtphase stark beeinträchtigt. Herzrate und Bewegungsaktivität zeigte einen 
ähnlichen tageszeitenabhängigen Verlauf. Die für die tageszeitenabhängige Regulierung von 
Blutdruck und Bewegungsaktivität wichtige Expression von Uhren-Genen im SCN war unverändert. 
Wohingegen die veränderte periphere Expression von Uhren-Genen im PVAT möglicherweise zur 
erhöhten Expression pro-inflammatorischer Moleküle beiträgt. Weiterführende Studien zur 
Untersuchung des Einflusses von RICTOR/mTORC2 auf die Gehirn-Fettgewebe-Achse könnten zu 
effizienteren Behandlungen von Bluthochdruck beitragen.  
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1. Introduction 
1.1 The circulatory system 
1.1.1 Organization and function of the circulatory system 
The circulatory system evolved as a consequence of increased complexity and size of multicellular 
organisms [1]. For these organisms, simple diffusion is not adequate to supply oxygen and 
nutrients to the innermost cells. The circulatory system is comprised of a large number of 
interconnected vessels different in structure, size and function [2]. It can be divided into the 
lymphatic and the cardiovascular system [2]. The lymphatic system assembles of lymph, lymph 
nodes and vessels, microvessels and is essential for returning excess interstitial fluid to the blood 
[1, 2]. The primary function of the cardiovascular system is to deliver blood throughout the body. 
It plays an essential role in the transport of oxygen and carbon dioxide, blood cells, nutrients and 
metabolic waste to and from metabolic active cells [3]. In addition, secondary roles developed [1]: 
(1) fast distribution of circulating hormones and neurotransmitter to responding cells, (2) 
strengthened immune response against pathogens and (3) improved heat dissipation to the 
surface of a multicellular organism. A simplified overview of the cardiovascular system in humans 
is given in figure 1-1-1.  
 
 
 
 
 
 
Figure 1-1-1: Overview of the cardiovascular system and circulation cycle of blood in humans. At 
the beginning of the circulation cycle, returning deoxygenated blood from the organs flows into the 
right atrium and enters the pulmonary circuit. Via the right ventricle blood is pumped into the 
pulmonary arteries and becomes oxygenated. Blood flows back to the left atrium of the heart and is 
pumped via the left ventricle and aorta into systemic arteries (systemic circuit). Capillaries provide 
organs with oxygen and nutrients before deoxygenated blood flows back to the right atrium of the 
heart and the circulation cycle starts again. Red colored blood vessels transport oxygenated blood, 
while blue colored vessels transport deoxygenated blood. Figure adapted from www.biology-
forums.com  
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On the basis of its anatomy, the cardiovascular system can be subdivided into the pulmonary and 
systemic circuit [1]. In both circuits, the heart is the major driver pumping blood and its  
components through different blood vessels to the lungs and systemic organs [1]. Deoxygenated 
blood is pumped from the right ventricle of the heart via pulmonary arteries to the lungs were it 
becomes oxygenated. When oxygenated, blood returns via the pulmonary veins to the left atrium 
of the heart entering the systemic circuit. Oxygenated blood is pumped into the arterial system 
consisting of arteries, arterioles and arterial capillaries providing organs with oxygen and 
nutrients. Deoxygenated blood enriched in metabolic by-products flows through the venous 
capillaries, venoles and veins back to the right atrium of the heart entering the pulmonary 
circulation again [3]. This process is also called the circulation cycle (figure 1-1-1). 
1.1.2 Blood vessels: Types and distribution 
Depending on their anatomy and function, blood vessels can be divided into three major types: 
(1) arteries carrying blood from the heart to the systemic organs or lungs, (2) capillaries were 
gases and nutrients are exchanged and (3) veins collecting capillary blood and carrying it back to 
the heart. Based on anatomical differences, arteries can be classified in elastic (conduit) arteries 
and muscular (distributing) arteries [4, 5]. Elastic arteries are located close to the heart and large 
in diameter [2]. They carry large volumes of blood under high-pressure away from the heart. 
Fluctuations in blood volumes are diminished by vessel wall properties (several layers of elastin) 
generating a more uniform blood flow. In humans, the largest elastic artery is the aorta (radius of 
~1.13 cm) originating at the aortic root. The aorta accommodates blood ejected from the left 
ventricle of the heart. The aorta branches into smaller arteries and arterioles, the smallest blood 
vessel type in the arterial bed accounting for the vast majority of blood vessels [2]. They can be 
referred to as muscular arteries (~0.4 cm in diameter). Their function is to reduce blood flow and 
to ensure adequate blood distribution within organs and tissues. As resistance of muscular 
arteries is rather stable, this type of blood vessels is also referred to as resistance arteries. Before 
transition to the venous system, arterioles branch into capillaries with an average size of ~ 3 µm 
and a total surface area of 1000 m2 in humans [1, 2]. The capillary network ensures exchange of 
nutrients, water and gases between blood and the surrounding tissue. This occurs mainly by 
simple diffusion. From the capillary network, blood flows through the venous system (venoles and 
veins) back to the heart. The venous system mainly functions as a collecting system for capillary 
blood and is characterized by low blood pressure [1]. To maintain blood flow in these conditions, 
veins are equipped with venous valves to avoid accumulation of blood in the lower parts of the 
human body. 
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1.1.3 Blood vessel wall: structure and function 
As described already in chapter 1.1.2, the cardiovascular system is not made of non-elastic vessels 
similar in structure and size. Depending on the blood vessel function, wall composition, the 
diameter and thickness vary widely throughout the cardiovascular system. In the broadest sense, 
the wall of most blood vessels is anatomically formed of three distinct layers [2]: tunica intima, 
tunica media and tunica adventitia (figure 1-1-2). 
 
 
 
 
 
 
 
 
Figure 1-1-2: Blood vessel wall structure of an artery, vein and capillary. The vessel wall of most 
arteries and veins is anatomically formed of three distinct layers: tunica intima, tunica media and 
tunica adventitia. Depending on function and localization of blood vessels, composition and 
thickness of individual vessel wall layers can vary widely. Capillaries are mainly composed of a single 
endothelial layer. Arrows indicate the direction of the blood flow. Red colored blood vessels 
illustrate oxygenated blood, while blue colored vessels indicate deoxygenated blood. Figure adapted 
from www.rci.rutgers.edu  
The tunica intima forms the innermost lining and consists of a single layer of endothelial cells 
(ECs) which directly faces the lumen of the blood vessel. In addition, an internal elastic lamina and 
fibro-elastic connective tissue provide stability and flexibility to the endothelial layer. No matter 
how distinct blood vessels are, a common characteristic is the single ECs layer [2]. The tunica 
media is the middle layer of a blood vessel. It is predominately made up elastic fibers and vascular 
smooth muscle cells (VSMCs) common to all blood vessels, but not capillaries. The third and 
outermost layer is the tunica adventitia and consists mainly of connective tissue [6]. Depending 
on blood vessel function and hierarchy, the manifestation of these three layers is more or less 
distinctive [1, 4]. Arteries such as the aorta are thick-walled. Multiple vascular smooth muscle cell 
layers and increased amounts of elastin and collagens are important for maintaining artery 
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function (high-pressure system) and blood flow. In addition, most systemic blood vessels are 
surrounded by perivascular adipose tissue (PVAT) [7], which secrets vasoactive substances 
regulating vascular tone and homeostasis [8, 9]. In chapter 1.3.3, PVAT composition and function 
will be discussed in more detail. 
1.1.3.1 Function of endothelial and vascular smooth muscle cells 
A single layer of ECs, the endothelium, forms the inner lining of the blood vessel. De novo 
formation of ECs into an endothelium occurs only in embryos. ECs originate from the early 
mesoderm involving differentiation of angioblasts and the formation of pre-blood vessels. 
Fibroblast growth factors (FGF) and vascular endothelial cell growth factor (VEGF) are crucial in 
this process. This process is called vasculogenesis [10, 11]. The expansion of existing blood vessels 
based on sprouting of ECs is called angiogenesis, mostly seen in wound healing processes or 
tumor growth [10]. Primarily, ECs provide a selective permeable barrier between the circulating 
blood and the blood vessel wall. In addition, other EC functions evolved including the regulation 
of vascular tone and homeostasis, response to inflammation and facilitation of blood flow [10]. 
ECs express a variety of receptors on the cell surface allowing the binding of circulating bioactive 
molecules. These include autacoids (e.g. acetylcholine, 5-hydroxytryptamine), hormones (e.g. 
insulin) and catecholamines (e.g. adrenalin, noradrenalin) [12, 13]. Receptor binding stimulates 
the secretion of vasoactive molecules from the endothelium (e.g. nitric oxide, prostaglandins) 
balancing vasodilation (relaxation) and vasoconstriction (contraction) of VSMCs in the tunica 
media. Various pathophysiological conditions including hypertension, obesity and diabetes can 
disturb physiological ECs function. 
VSMCs primary function is to adapt vascular tone to physiological requirements. Through the 
contraction and relaxation of VSMCs, blood vessel diameter and thereby blood pressure, flow and 
blood distribution within organs is regulated [1]. VSMCs are differentiated [14] and express a 
unique combination of receptors, ion channels and contractile molecules to ensure VSMC 
contractile and dilatory properties. Interestingly, VSMCs maintain the ability to change their 
phenotype to a dedifferentiated state upon changes in environmental cues [14]. Dedifferentiated 
VSMCs have a distinct cell shape and function. These cells are characterized by a significant 
increase in migration, proliferation, and a different gene and protein expression profile. 
Dedifferentiation can be observed in the progression of hypertension, arteriosclerosis, and after 
vascular wall injury. 
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1.1.3.2 Mechanism of vasodilation in arteries 
Vasodilation and vasoconstriction of blood vessels adjust vascular resistance adapting blood 
pressure and flow to the needs of an organism and environmental cues. The different layers of a 
blood vessel, particularly ECs and VSMCs, play a key role in these processes. 
In 1980, Furchgott and Zawadzki were the first describing the important role of ECs in the 
regulation of blood vessel tone. They demonstrated the release of an endothelium-derived 
relaxation factor (EDRF) upon acetylcholine stimulus [15]. This EDRF has later been discovered to 
be nitric oxide (NO) [16] causing vasodilation of underlying VSMCs. Since then other circulating 
factors have been identified to trigger EDRFs production in ECs. These include insulin [17, 18], 
adiponectin [19, 20] and thyroid hormones [21]. Gaseous NO is able to diffuse freely across 
membranes and is the best characterized vasoactive molecule released from ECs [22, 23]. NO has 
multiple effects on the blood vessel wall. It inhibits adhesion of platelets and leukocytes to the 
endothelium, sustains vascular repair mechanisms controlling VSMCs migration and proliferation 
as well as stimulating EC migration. In ECs, NO is biosynthesized from the amino acid L-argenine 
and NADPH constitutively by the calcium (Ca2+)-dependent endothelial nitric oxide synthase 
(eNOS; also known as NOS III). Synthesis can be adjusted upon stimuli including circulating 
bioactive molecules. eNOS is exclusively expressed in ECs. Two other isoforms have been 
identified sharing up to 60 % homology in the amino acid sequence [22]. Similar to eNOS, neural 
NOS (nNOS; also known as NOS I) is constitutively expressed, but only in central and peripheral 
neuronal cells. Inducible NOS (iNOS; also known as NOS II) activity is independent of intracellular 
Ca2+ concentration. iNOS expression is mainly found in macrophages, abnormal cells states such 
as after myocardial infarction and other pathophysiological conditions. An overview of the NO 
synthesis in ECs is given in figure 1-1-3. 
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Figure 1-1-3: Production of nitric oxide in endothelial cells and relaxation of vascular smooth 
muscle cells. Upon binding of various vasoactive molecules and/or shear stress, nitric oxide is 
synthesized in endothelial cells from L-arginine by endothelial nitric oxide synthase. As a gas, nitric 
oxide diffuses freely to underlying vascular smooth muscle cells. Nitric oxide enhances the 
conversion of guanosine-5'-triphosphate into cyclic guanosine-monophosphate promoting vascular 
smooth muscle cell relaxation due to decreased intracellular Ca
2+
 concentration. Ach (acetylcholine), 
M3 (M3-muscarinic receptors), PLC (Phospholipase C), PIP2 (phosphatidylinositol 4, 5-bisphosphate), 
DAG (Diacylglycerol), L-Arg (L-Arginine), eNOS (endothelial nitric oxide synthase), Ca
2+
 (Calcium), IP3 
(Inositol-1,4,5-trisphosphat), NO (nitric oxide), GTP (Guanosine-5'-triphosphate), sGC (Soluble 
guanylate cyclase), cGMP (Cyclic guanosinmonophosphat), PKG (Proteinkinase G). Figure adapted 
from [13, 23]. 
Upon binding of acetylcholine to its receptor on ECs membrane, phospholipase C (PLC) becomes 
activated leading to the conversion of phosphatidylinositol 4, 5-bisphosphate (PIP2) to inositol 1, 
4, 5- triphosphate (IP3) and diacylglycerol (DAG). Increased intracellular IP3 concentration 
facilitates Ca2+-influx into ECs via Ca2+-channels, which activates calmodulin. Calmodulin binds to 
eNOS increasing its activity promoting the synthesis of NO. NO diffuses to VSMCs leading to an 
intracellular increase in soluble guanylate cyclase (sGC) activity. sGC converts guanosine-5'-
triphosphate (GTP) to cyclic guanosine 3`, 5`-monophosphate (cGMP). cGMP activates protein 
kinase G (PKG) decreasing intracellular Ca2+-concentration and thus, promoting vasodilation of 
VSMCs. Under pathophysiological conditions including hypertension, obesity and diabetes, but 
also during ageing, NO bioavailability is reduced as a consequence of ECs dysfunction [13, 24]. 
This favors vasoconstriction of VSMCs [25]. 
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1.1.3.3 Mechanism of vasoconstriction in arteries 
In addition to its ability to release EDRFs and EDHF, the endothelium produces endothelium-
derived contracting factors (EDCFs) which cause vasoconstriction of underlying VSMCs [13, 26]. 
Summarized in figure 1-1-4, the release of EDCFs can be increased upon activation of ECs by 5-
hydroxytryptamine (5-HT), angiotensin II (ANG II) and chronically elevated stretch, but also other 
substances including adenosine diphosphate and superoxide anion (O2
-) [27, 28].  
 
 
 
 
 
 
 
 
 
 
Figure 1-1-4: Endothelium-derived contracting factors. Upon binding of different vasoactive 
substances to corresponding receptors on endothelial cell surface, generation of endothelium-
derived contracting factors is induced. The release of these factors causes the contraction of 
underlying vascular smooth muscle cells. ACh (acetylcholine), ANGII (angiotensin II), AT-1 
(angiotensin receptor 1), EDCFs (endothelium- derived contracting factors), M3 (M3-muscarinic 
receptors), R (other vasoactive substances), R-R (receptor for other vasoactive substances), 5-HT (5-
hydroxytryptamine). Figure adapted from [13]. 
Under physiological conditions, the effect of EDCFs is superimposed mainly by NO. ECs 
dysfunction and reduced NO bioavailability as seen in hypertension facilitate the release of EDCFs 
causing increased vasoconstriction of VSMCs. The vast majority of EDCFs belongs to the group of 
prostaglandins [28], which are synthesized from arachidonic acid through the cyclooxygenase 
(COX) in ECs. Prostaglandins play a key role in endothelium-dependent contractions as COX 
inhibition prevent nearly all endothelium-dependent contractions [27]. Upon release, EDCFs bind 
to their specific G-protein-coupled receptors (mostly TP receptors) on the VSMCs surface, 
initiating vasoconstriction. 
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1.1.4 Blood pressure regulation 
Arterial blood pressure is a function of four different factors within the cardiovascular system: 
peripheral resistance, cardiac output, cardiac compliance and blood volume [1]. Determinates are 
subjected to a broad range of regulations. The medullary cardiovascular center (MCC) is located in 
the medulla oblongata and part of the short-term regulation of arterial blood pressure. The MCC 
coordinates rapid neuronal response to changes in baroreceptor (sensitive to transmural pressure 
changes of the blood vessel wall) and chemoreceptor signaling [1]. MCC output results in fast 
modifications of cardiac output and peripheral resistance via sympathetic and parasympathetic 
nerve activity [3]. Sympathetic response increases cardiac output and compliance via 
noradrenaline release which acts on β1-adrenergic receptors on cardiac cells surface. 
Parasympathetic output decreases mainly cardiac output. Modulation of peripheral resistance is 
mostly achieved via sympathetic nervous activity [3]. The released neurotransmitter 
noradrenaline (postganglion sympathetic nerves) and adrenaline (adrenal medulla) act on 
adrenergic receptors expressed on VSMCs surface. Whether vasodilation or vasoconstriction is 
induced depends on e.g. the agonist released and the adrenergic receptor expressed [1]. In 
addition, a broad range of tissues and organs are known to secrete humoral and non-humoral 
factors which affect short-term and intermediate regulation of arterial blood pressure [1]. Insulin 
secreted by the pancreas increases NO bioavailability contributing to vasodilation of VSMCs [29]. 
It is well known that adipose tissue releases a variety of substances possessing vasoactive 
properties [30, 31]. Substances include adiponectin, leptin, plasminogen-activated factor 1 (PAI-1) 
and TNF-α. An implication in arterial blood pressure regulation is also well established for the 
natriuretic peptides (NPs) [32]. Atrial (ANP) and brain NP (BNP) are mainly synthesized by the 
atrial myocardium and ventricles of the heart, respectively. Under physiological conditions, ANP 
and BNP inhibit e.g. sympathetic activity to cause bradycardia and are involved in the long-term 
control of arterial blood pressure by regulating sodium retention in the kidney [3]. Long-term 
regulation of blood pressure is achieved mainly via renal fluid volume regulation and the renin-
angiotensin-aldosterone system (RAAS). Major effectors are the lymphatic system modulating 
extracellular fluid volume (ECFV) and sodium and water resorption of the kidneys. This in turn 
changes total blood volume which has a profound effect on cardiac output and arterial blood 
pressure. Similar to short-term regulation, the sympathetic nervous system is also implicated in 
long-term control of arterial blood pressure [33]. Interestingly, arterial blood pressure shows 
time-of-days dependent variations which are influenced by the master circadian clock in the 
suprachiasmatic nucleus and explained in detail in chapter 1.2. 
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1.1.5 Dysregulation of blood pressure in hypertension 
Dysregulation of arterial blood pressure can cause hypertension. It is one of the most common 
cardiovascular diseases in human adults [34]. It is characterized by chronically elevated blood 
pressure with blood pressure readings > 140/90 mmHg in humans age 20 and older, and is 
categorized into different stages (Table 1-1-1). In addition, hypertension can be classified 
according to the (1) severity of the vascular disease (mild, moderate, serve or malignant), (2) the 
arterial pressure increase (diastolic, systolic or both) and (3) etiology (essential or secondary) [35]. 
The prevalence of hypertension in adults 35 to 64 years of age varies widely among countries in 
Europe and North America. Highest rates have been found in Germany (~55 %), lowest in Italy 
(~38 %), while rates in the United States (~30 %) and Canada (~27 %) are only half of those in 
Germany [36, 37]. It was shown that 90 to 95 % of patients suffer from essential hypertension 
(also known as primary or idiopathic) with unknown cause explaining elevations in blood pressure 
[38]. Only 5 to 10 % of patients suffer from secondary hypertension, which can be a consequence 
of kidney disease, the cardiovascular or endocrine system as well as pregnancy and medication 
side effects [39]. 
Table 1-1-1: Blood pressure categories according to the American Heart Association definition. 
Blood pressure can be considered to be as normal, if blood pressure readings are less than 120/80 
mmHg. Table adapted from www.heart.org 
 
Blood pressure category Systolic (mm Hg)  Diastolic (mmHg) 
Normal < 120 and < 80 
Prehypertension 120 – 139 or 80 – 89 
High blood pressure (Hypertension) Stage 1 140 – 159 or 90 – 99 
High blood pressure (Hypertension) Stage 2 160 – 179 or 100 - 109 
Hypertensive crisis > 180 or > 110 
 
Triggers of essential hypertension are varied and can arise from the combination of different 
genetic and demographic circumstances [40]. In human adults age 60 to 69, the prevalence to 
suffer from hypertension is 69 % compared with younger people and the onset of hypertension in 
women is earlier than in men [41]. In addition, various environmental factors can influence the 
onset and severity of hypertension. These factors include bodyweight, physical activity, diet and 
smoking [42, 43].  
Different pathophysiological factors and mechanisms are implicated in the onset of essential 
hypertension. In animal models of hypertension, an imbalance between the sympathetic and 
parasympathetic nervous system has been observed to contribute to the development of 
hypertension. In humans, sympathetic hyperactivity as well as increased levels of 
neurotransmitters adrenalin and noradrenalin has been observed in normotensive people with a 
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positive family history of hypertension [44, 45]. Similar, obese and diabetic patients are often 
found to be hypertensive combined with increased sympathetic nervous activity compared to 
lean controls. This might be due to increased plasma insulin (hyperinsulinemia) to compensate 
insulin resistance [46]. In addition, insulin resistance has been linked to endothelial dysfunction 
promoting the development of hypertension [47]. Long-term sympathetic hyperactivity is also 
associated with vascular remodeling of resistance arteries [48]. Changes in blood vessel wall 
structure and reactivity are well known to increase peripheral vascular resistance and thus arterial 
blood pressure [48]. In addition, structural changes of the blood vessel wall are often 
accompanied by endothelial dysfunction [49, 50]. This pathophysiological state is mainly 
characterized by increased oxidative stress leading to a reduction of NO and prostacyclin 
bioavailability. This favors vasoconstrictor production and the progression of hypertension. In 
addition, ANG II is a well-known contributor of oxidant production in the blood vessel wall. 
Pathophysiological action of ANG II on ECs up-regulates the formation of oxidant peroxynitrite 
(ONOO-) reducing NO action on VSMCs. Elevated levels of ANG II often correlate with changes in 
kidney function and RAAS. 
If untreated, hypertension can cause a variety of health consequences referred to as end-organ 
damage such as different heart and coronary arteries diseases, stroke, kidney damage and 
peripheral vascular diseases. 
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1.2 Impact of the mammalian circadian clock on the cardiovascular system 
1.2.1 The mammalian circadian clock: definition and anatomical organization 
Organisms are subjected to rhythmic changes of the environment. Most important are recurring 
day and night cycles based on earth rotation as well as seasonal cycles caused by the earth 
orbiting the sun. Organisms have adapted their physiology and behavior according to these 
changes. As a consequence, biological clocks evolved generating endogenous rhythms. Depending 
on the length of the period, rhythms can be infradian (< 24 hours), ultradian (> 24 hours) or 
circadian (~ 24 hours). A fundamental feature of circadian rhythms is their entrainment to 
exogenous timing signals (term: Zeitgeber) and its persistence also in the absence of such signals 
(free-running) [51]. It is important to distinguish between circadian and daily rhythms. The latter 
have a period of ~ 24 hours and are driven by recurring environmental cues, but do not persist 
under constant conditions (e.g. complete darkness). In mammals, the primary exogenous timing 
signal is light, which is translated via ocular photoreception into an endogenous timing system 
governed by the circadian clock [51]. The mammalian circadian clock is organized in a hierarchy of 
oscillators (figure 1-2-1) [52]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2-1: Hierarchical organization of the mammalian circadian clock. The master circadian 
clock is located at the suprachiasmatic nucleus (SCN) translating exogenous light signals into an 
endogenous timing system. Via neurohumoral signals, the SCN affects physiology/behavior directly 
or synchronizes peripheral clocks affecting tissue-specific metabolism. Peripheral clocks can be 
entrained to other environmental cues such as temperature and feeding behaviors. 
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The master circadian clock is located in the suprachiasmatic nucleus (SCN). The SCN is located at 
the anterior hypothalamus dorsal to the optic chiasm and bilateral to the third ventricle [53, 54]. 
The SCN is mainly entrained to light stimuli. In humans, the SCN is composed of ~ 50000 neurons 
(mice ~ 20000). To ensure stable master circadian clock oscillation and output, SCN neurons are 
synchronized with each other through unique processes [55]. Three different mechanisms are 
believed to play a fundamental role in the “coupling of SCN-neurons”. These include 
neuropeptidergic signaling, electrical synapses and synaptic potentials [56-61]. In general, the SCN 
can be considered as a master synchronizer. It coordinates through neurohumoral factors 
independent “slave” peripheral circadian clocks in various tissues to achieve an interconnected 
circadian rhythm on whole body level [52]. Peripheral circadian clocks autonomously control 
tissue specific circadian metabolism. Although similar on the molecular basis (see chapter 1.2.2), 
master and peripheral clocks exhibit some profound differences. First, cells in peripheral tissues 
lack the ability of coupling and thus network properties [62]. Unlike SCN explants, which can be 
caped for weeks in culture without any changes in gene expression oscillation, in peripheral 
tissues oscillating gene expression patterns dampen quickly after a few days ex vivo. However, 
disruption of SCN neuron coupling leads to arrhythmic gene expression patterns [55]. The second 
major difference is the ability of peripheral clocks to respond not only to SCN-derived signals, but 
also to other stimuli such as temperature, feeding cues (e.g. nutrient availability) and hormones 
[63-65]. In contrast, the SCN primarily respond to light stimuli. SCN neurons are blind to their own 
signals [52] and can’t be entrained to “peripheral zeitgeber” as long as coupled with each other.  
To achieve the accuracy and reliability needed for interconnected circadian rhythms in different 
tissues, the molecular mechanism behind must be well-designed. Dysfunctional circadian clocks 
can cause serious health problems in mice which manifest in disturbed function of adipose tissue 
[66-68], pancreas [69] and the cardiovascular system [70, 71]. The main molecular drivers of the 
mammalian circadian clock will be discussed in the following section.  
 
1.2.2 Molecular components of the mammalian circadian clock 
The molecular basis of the circadian clock is similar in the SCN and peripheral tissues [72] and is 
illustrated in figure 1-2-2. It consists of interconnected and auto-regulated transcriptional-
translational feedback loops driving approximately 24 hour expression patterns of different core 
clock genes. 
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Figure 1-2-2: Molecular components of the mammalian circadian clock. 24 hour rhythms in 
physiology and behavior are achieved through interconnected transcriptional-translational feedback 
loops. These loops are composed of a set of transcriptional activators (green), which induce 
expression of its own repressors (red). To drive rhythmicity of biological processes, activators induce 
transcription of clock-controlled genes (Ccg’s). Bmal1 (Brain-muscle arnt like 1), Clock (Circadian 
locomotor output cycles kaput), Npas2 (Neuronal PAS domain protein 2), C/N (CLOCK/NPAS2), C/B 
(CLOCK/BMAL1), Rev-Erb-α/β (nuclear receptor subfamily 1, group D, member 1 and 2), Rorα/β/γ 
(retinoic acid-related orphan receptor alpha and beta), PERs (PERIOD proteins), CRYs 
(CRYPTOCHROME proteins), HDAC (histone deacetylase), HMTs (histone methyltransferase), DBHS 
(members of the Drosophila behavior human splicing family), CK1δ/ε (Casein kinases 1δ and 1ε). 
Figure adapted from [52]. 
In the primary feedback loop, the positive limp consists of the genes Brain-muscle arnt like 1 
(Bmal1), Circadian locomotor output cycles kaput (Clock) and Neuronal PAS domain protein 2 
(Npas2) encoding basic helix loop helix; Period-Arnt-Single minded (bHLH-PAS) proteins. 
Heterodimers of BMAL1/CLOCK or BMAL1/NPAS2 initiate transcription of target genes with E-box 
element-containing promoters [51]. Genes include those of Period (Per1, Per2, Per3) and 
Cryptochrome (Cry1, Cry2). PER and CRY proteins are part of the negative limb of the primary 
feedback loop. PER and CRY dimerize, translocate to the nucleus and repress the transcriptional 
activity of BMAL1/CLOCK and BMAL1/NPAS2 [72]. Stability and nuclear translocation of PER/CRY 
is regulated by post-translational modifications (e.g. phosphorylation, ubiquitination) involving 
e.g. Casein kinases 1δ and 1ε (CK1δ; CK1ε) and Histone methyltransferases (HMTs) [73-75]. This is 
necessary to reset the transcriptional cycle. In addition, BMAL1/CLOCK and BMAL1/NPAS2 induce 
a second feedback loop interconnected to the feedback loop already described. Expressed 
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retinoic acid-related orphan receptor proteins REV-ERB’s (REV-ERB α and β) and ROR’s (RORα, β 
and γ), compete for ROR-response elements (RORE) within the promoter region of Bmal1 [76]. 
REV-ERB’s have been found to repress, while ROR’s activate Bmal1 transcription [76-78]. Both 
transcription regulating elements are necessary to ensure normal period regulation and precision 
of the mammalian circadian clock. Clock output manifests in adapted oscillating gene expression 
of clock-controlled genes (ccg’s) regulating a variety of metabolic processes and organ function. 
Ccg´s include transcription factors such as D site albumin promoter binding protein (Dbp), nuclear 
factors interleukin 3, regulated (Nfil3) or peroxisome proliferator activated receptor alpha/beta 
(Pparα/β). 
1.2.3 Mammalian circadian clock and metabolism 
Circadian clocks might have evolved to balance energy intake, storage and utilization. Thus, it is 
not surprising that in humans and rodents, many aspects of the physiology and metabolism 
display circadian rhythmicity [79, 80]. These include body temperature, activity, lipid metabolism, 
hormone secretion, blood pressure and heart rate regulation. To achieve rhythmicity, metabolism 
and circadian clock are molecularly interconnected with each other [80]. 5 to 10 % of all genes 
expressed in a cell oscillate in a day-time dependent manner [81-84]. In peripheral tissues, this is 
achieved through master circadian clock-output, but also feedback loops set-up between 
molecular components of peripheral circadian clocks and different nutrient sensors [75, 80, 85]. 
Nutrient sensors include nicotinamide phosphoribosyltransferase (NAMPT), sirtuin1 (SIRT1), 
protein kinase, AMP-activated, alpha 1 catalytic subunit (Prkaa1; also known as AMPK) and 
various transcription factors (e.g. DBP, NFIL3, PPAR’s, ROR’s, PGC-1α, SIRT1). These proteins 
transmit information about the cellular nutrient state to coordinate metabolic processes. In 
addition, input from nutrient sensors has been found to reset the phase of peripheral circadian 
clocks [52]. Thus, peripheral circadian clocks not only relay on input from the master circadian 
clock in the SCN. This has been underpinned by a study in experimentally SCN-lesioned mice as 
peripheral clocks retain their ability to maintain individual synchronal expression of clock genes, 
but showed phase misalignment between individual tissues clocks [86]. Thus, it is unsurprising, 
that disruption of the circadian rhythm and its molecular basis impacts many physiological 
processes. In our modern society, shift work, jet lag and over-nutrition are assumed to induce 
circadian clock and metabolic misalignment [87, 88]. Progression of pathophysiological conditions 
including cardiovascular diseases, obesity and diabetes are assumed to be a consequence of this 
misalignment. In the following paragraph, peripheral circadian clocks in the cardiovascular system 
and adipose tissue will be discussed in more details. 
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1.2.4 Circadian clock and the cardiovascular system 
Various cardiovascular processes including blood pressure, vascular function and heart rate 
exhibit day-of-time dependent variations [89-92]. These changes arise through various 
endogenous and exogenous signals. Although mechanistically incompletely understood, these 
signals are aligned to the circadian rhythm and orchestrate cardiovascular functions [71, 93, 94]. 
The SCN is thought to play an important role in this process communicating integrated exogenous 
signals via the endocrine and autonomic nervous system [95, 96]. This might affect different 
hypothalamic regions associated with blood pressure regulation, RAA system, endothelial 
regulation of vascular tone and circulating vasoactive peptides [71]. Epidemiological studies 
indicate an association of circadian misalignment and the onset of cardiovascular diseases 
underscoring the importance of the circadian clock in this regard [87, 88, 97, 98]. In shift workers, 
the risk of cardiovascular diseases is increased relative to daytime workers [98]. Acute myocardial 
infarctions, stroke and ventricular tachycardia have been reported to manifest mainly in the 
morning hours [99-101]. Growing evidence has been accumulating for a direct role of the 
molecular components of the circadian clock regulating cardiovascular functions [71]. Targeted 
deletions of core clock genes in mice further strengthened this association. Deletion of Per2 
decreases endothelial NO production impairing vasorelaxation of VSMCs [102]. Cry1/2 double 
knockout mice were shown to have increased circulating aldosterone level resulting in salt-
sensitive hypertension [103]. VSMC-specific deletion of Pparg inhibits Bmal1 expression leading to 
elevated mean arterial pressure and heart rate [104]. This further strengthened the association of 
metabolic dysfunction, circadian misalignment and cardiovascular diseases. Studies in patients 
diagnosed with type 2 diabetes mellitus (T2DM) uncovered elevated blood pressure and heart 
rate associated with defects in 24 hour blood pressure rhythmicity [105]. Mouse models of T2DM 
showed a similar phenotype complemented with changes in circulating vasoactive hormones, 
vascular and sympathetic tone [106-109]. Interestingly, rhythmic food intake is abolished in T2DM 
mouse models and mice fed with high-fat diet, that can be restored with a strict feeding regime 
[110, 111]. This suggests a profound relationship of the circadian clock and the metabolism in 
blood pressure regulation. In addition, adipose tissue, particularly relevant to metabolic 
homeostasis, is essential for the control of cardiovascular functions [9, 30, 112]. Circadian 
misalignment in adipose tissue might negatively affect the activity of the cardiovascular system 
[68]. 
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1.3 Adipose tissue 
1.3.1 Adipose tissue function 
The classical roles of adipose tissue are to store free fatty acids (FFA) and to release them during 
periods of fasting to ensure sufficient energy availability [113]. Additional functions such as non-
shivering thermogenesis, protection of organs against mechanical damage and thermal insulation 
evolved [113]. However, over the last 20 years, adipose tissue has been recognized as a complex 
endocrine organ [114, 115]. Adipose tissue communicates with and plays a critical role in the 
regulation of function of nearly all other organs. This is achieved through endocrine and paracrine 
interactions. Analysis of adipose tissue secretory profile revealed a variety of hormones (termed 
adipokines), cytokines and other bioactive molecules secreted [114, 116]. Most prominent 
adipokines are leptin and adiponectin as well as cytokines including interleukins and TNF-α. 
Secreted factors have been implicated in the physiological responses including appetite control, 
hormone secretion, inflammatory processes and vascular reactivity [113].  
On the other hand, adipose tissue function is controlled through a variety of hormonal, neuronal 
and local factors (autocrine interaction) [113, 117]. Most prominent hormones are insulin and 
glucagon; both are secreted from pancreatic cells, balancing FFA storage and release. Adipose 
tissue is highly innervated by nerve endings from the parasympathetic and sympathetic nervous 
system to control tissue function [118]. CNS output has been implicated in lipolysis [119] and 
leptin secretion [120]. In addition, the parasympathetic nervous system plays a critical role in 
regulating adipose tissue insulin sensitivity [121].  
1.3.2 Structural heterogeneity of adipose tissue 
Adipose tissue mainly consists of adipocytes [122]. In addition, other cell types including 
preadipocytes, macrophages, fibroblasts and endothelial cells have been found and termed as 
stromal vascular fraction (SVF). The SVF accounts for a variety of factors secreted from adipose 
tissue and is indispensable for adipose tissue function [123]. Depending on adipocyte morphology 
and function, at least two distinct adipose tissue types are known: brown and white adipocytes 
(Figure 1-3-1) [124, 125].   
Introduction 
17 
 
  
 
 
 
 
 
Figure 1-3-1: Morphology and function of white and brown adipocytes. A white adipocyte contains 
one large unilocular lipid droplet. Cytoplasm area is limited containing a few mitochondria and a 
squeezed nucleus. In contrast, a typical brown adipocyte comprises multilocular lipid droplets and 
densely packed mitochondria. For non-shivering thermogenesis, brown adipocyte mitochondria are 
uniquely equipped with uncoupling protein 1 (UCP1). FFA (free fatty acids). 
White adipose tissue (WAT) is characterized by adipocytes large in diameter (25 - 200 μm) 
containing unilocular lipid droplets [126]. WAT is the most abundant adipose tissue type in 
humans and mice. It is best known for body’s largest energy store and the release of multiple 
adipokines (adiponectin, leptin) and cytokines (TNF-α, IL-6). In contrast, brown adipose tissue 
(BAT) is less abundant and composed of small multilocular adipocytes (< 60 μm) enriched in 
mitochondria [117, 127]. BAT mainly contributes to heat production through non-shivering 
thermogenesis. For this purpose, brown adipocytes uniquely express uncoupling protein 1 (UCP1) 
necessary for mitochondrial uncoupling of oxidative phosphorylation [128] and heat production 
instead of ATP. Other BAT specific markers are cell death-inducing DNA fragmentation factor, 
alpha subunit-like effector A (CIDEA), PR domain containing 16 (PRDM16) and PPARgamma co-
activator 1 alpha (PGC1α) [117, 124]. Many years, BAT has been thought to play a role only in 
rodents and human infants. This assumption has completely changed as distinct BAT deports in 
the neck and trunk region has been reported by Nedergaard and Cannon in human adults in 2007 
[129]. Additional studies confirmed these findings [130, 131]. In addition, both adipose tissue 
types are found in different anatomical areas of the body in both humans and mice (Figure 1-3-2) 
[132]. Depending on the anatomical area, adipose tissue depots are different in structure, cell 
composition and biological function. One of these adipose tissue depots is perivascular adipose 
tissue. 
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Figure 1-3-2: Anatomical localization of different adipose tissue depots throughout the human 
body. Most abundant are visceral and subcutaneous adipose tissue depots. Other depots are located 
around the kidney, heart, bone marrow, pulmonary and systemic arteries. Figure adapted from 
[133]. 
 
1.3.3 Perivascular adipose tissue 
1.3.3.1 Structure and function 
Perivascular adipose tissue (PVAT) surrounds most systemic blood vessels. It lies directly on the 
adventitia without any separating structure. Although initially thought to play only a role in 
structural support of underlying blood vessel, PVAT has been recognized to regulate blood vessel 
tone and homeostasis [9, 134, 135].  
Referring to the different types of adipose tissue, PVAT can be classified as either white or brown-
like adipose tissue. In mice, Fitzgibbons et al. identified PVAT surrounding the thoracic aorta as 
brown-like [7]. In this study, perivascular adipocytes express a nearly identical BAT gene profile 
including Ucp-1, Cidea and Prdm16. Furthermore, perivascular and brown adipocyte morphology 
resembles in multilocular lipid droplets and abundant mitochondria. In contrast, PVAT 
surrounding the abdominal aorta [136], mesenteric [137] and coronary arteries [138] can be 
referred to as white. The heterogeneity of regional PVAT depots localized in different vascular 
beds further translates to distinct secretory profiles [137].  
In accordance to its specific function in the regulation of blood vessel reactivity, PVAT properties 
differ from other adipose tissue depots [138]. PVAT has distinct gene expression and secretory 
profiles, but also perivascular adipocytes with a distinct developmental stage [138]. PVAT consist 
of adipocytes and SVF. Similar to other adipose tissue depots, SVF is crucial for PVAT function and 
secretes bioactive molecules [139]. This becomes clearly evident under pathophysiological 
conditions such as hypertension and obesity [140-142] and will be reviewed in chapters 1.3.3.3 
and 1.3.3.4.  
Perivascular 
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Bone marrow 
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1.3.3.2 Paracrine effects of PVAT on blood vessel reactivity 
In 1991, Soltis and Cassis were the first describing the importance of PVAT on blood vessel 
reactivity [8]. Performing ex vivo organ chamber experiments, they demonstrated reduced 
vasoconstriction to noradrenalin of aortic rings with PVAT compared to aortic rings without PVAT 
isolated from rats. Almost a decade later, these findings were rediscovered [143, 144]. Today, 
PVAT is widely accepted as an endocrine organ regulating vascular tone and homeostasis.  
Similar to other adipose tissues, PVAT secretes a variety of substances mediating PVAT vasoactive 
properties. Substances can induce vasodilation, vasoconstriction or both of underlying VSMCs. 
Under physiological conditions, PVAT exerts vasodilating properties as secretion of 
vasoconstrictors is low and superimposed by vasodilators. Adiponectin [145], visfatin [146] and 
methyl palmitate [147] have been discovered as PVAT-derived relaxing factors (PDRFs) promoting 
vasodilation. Leptin [148], hydrogen peroxide (H2O2) as well as TNF-α and IL-6 contribute to blood 
vessel tone by their vasodilatory and vasocontractile properties. Although still under 
investigation, mechanisms mediating PVAT vasodilating properties are diverse. They can be 
endothelium-dependent or independent and involve the action of various vasorelaxing 
metabolites [149-152]. Mechanisms independent of the endothelium involve activation of VSMC 
potassium channels (mainly KATP; KV; KBKa) [153-156]. Interestingly, effects of some PVAT-derived 
vasoactive substances such as TNF-α and H2O2 highly depend on the vascular bed, species and 
their concentrations [31, 157]. The role of nerve endings in PVAT is poorly understood and 
controversial. Dukrovska et al. reported that the release of vasoactive substances from PVAT does 
not involve nerve endings [154], other hypothesized that nerve endings are important for normal 
PVAT function [158]. 
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Figure 1-3-3: PVAT-derived vasoactive substances implicated in the regulation of vascular 
reactivity. PVAT vasoactive properties are mediated through a variety of substances secreted from 
different cells types which reside within PVAT. Anti- and pro-contractile properties can be dependent 
and independent of the endothelium mediating VSMC relaxation and contraction as well as 
proliferation. Figure adapted from [159]. 
 
Interestingly, some studies ruled out the release of PVAT-derived vasocontracting factors (PDCFs). 
These include not only H2O2, leptin, TNF-α and IL-6, but also different angiopeptides, resistin and 
reactive oxygen species (ROS) [159, 160]. PDCFs have been implicated in mediating 
vasoconstriction of underlying VSMCs, an observation which has already been made by Soltis and 
Cassis [8]. Mechanisms might be Ca2+-dependent and independent [31, 161]. Intriguingly, the 
release of PDCFs has been reported to be increased under pathophysiological conditions [9]. 
Angiotensin II (ANGII) promotes the conversion of NO into oxygen free radicals impairing 
vasodilation of VSMCs [162]. Elevated ANGII levels have been further connected to the increased 
secretion of pro-inflammatory and adhesion-promoting molecules. This enhances adhesion and 
migration of monocytes through the blood vessels promoting vascular dysfunction. 
 
1.3.3.3 Role of PVAT in hypertension 
As already described in chapter 1.1.5, hypertension is a multifactorial disorder and characterized 
by an increase in blood pressure. In the vasculature, ECs dysfunction and VSMC remodeling are 
two widely accepted states contributing to the progression of hypertension. The role of PVAT is 
less well understood. Data from a few rodent studies pointed out that reduction in PVAT mass 
contributes to the loss of PVAT anti-contractile properties [147, 163-165]. This has been 
associated with increased vasoconstriction in different vascular beds. The mechanism how PVAT’s 
anti-contractile properties get lost in hypertension is still a question of ongoing research. It is 
conceivable, that different mechanisms have to be taken into consideration.  
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Secretome analysis performed by Ruan et al. in hypertensive DOCA-salt rats, identified 
complement 3 as the most abundant molecule secreted from thoracic PVAT [165]. Complement 3 
has been implicated in vascular remodeling, a common process in hypertension. However, 
dysregulation of VSMC vasodilatory response to PVAT-derived anti-contractile signals has also 
been shown [166]. Several independent studies revealed a reduction in PDRFs secretion from 
PVAT. This includes methyl palmitate, leptin and adiponectin, which could be linked to elevations 
in VSMC constriction [147, 156]. Loss of PVAT anti-contractile properties could be in part 
mediated through an increase in pro-contractile molecules released from PVAT and macrophages 
such as TNF-α and superoxide anions [167]. Elevated TNF-α levels further promote the secretion 
of other pro-inflammatory cytokines (e.g. IL-6) from PVAT triggering vessel wall inflammation. 
Vascular inflammation negatively impacts vessel wall properties and is a common characteristic of 
hypertension [135].  
PVAT infiltrating cells might further contribute to PVAT dysfunction in hypertension. Withers et al. 
demonstrated that deletion of monocytes protects mice against experimentally induced 
hypertension [139]. Macrophages are a well-known source of TNF-α [168]. In PVAT, increased 
TNF-α levels have been reported to reduce adiponectin secretion diminishing NO bioavailability to 
VSMC [169-172]. Thus, it is likely, that infiltrating macrophages and vessel wall inflammation 
contribute to loss of PVAT anti-contractile properties during hypertension. 
1.3.3.4 Role in obesity 
In situations with balanced energy intake and expenditure, PVAT exerts protective and beneficial 
properties on the vasculature. Properties are directly related to PVAT mass. There is growing 
evidence that obesity contributes to PVAT dysfunction. Mechanisms are still incompletely 
understood. Studies in humans and rodents emphasize that changes in PVAT secretory profile as 
well as infiltrating immune cells are integral parts in this process. In obese humans, PVAT mass is 
increased and anti-contractile properties are diminished [173]. This has been linked to alterations 
in the secretome of PVAT and increased PDCFs and pro-inflammatory molecules secretion. Studies 
in mouse models of obesity pointed into the same direction. Genetically or HFD-induced obesity 
promotes PVAT dysfunction [138, 174, 175]. In line with other adipose tissue depots, secretion of 
vasoactive substances is changed. For instance, the release of adiponectin from perivascular 
adipocytes is reduced [176], while leptin secretion is enhanced [138, 177]. Both contribute to 
endothelial dysfunction diminishing NO bioavailability and promote vasoconstriction of VSMC. 
Interestingly, in obese mice, hypertrophic perivascular adipocytes promote the generation of a 
hypoxic, pro-inflammatory and oxidative environment within the vasculature [173]. This might be 
in part triggered through changes in PVAT secretory profile and manifests in increased 
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macrophage infiltration, ROS production as well as eNOS dysfunction [175, 177]. Interestingly, 
insulin mediated vasodilation of VSMC can be modulated by adipokines [178] and changes in 
adipokine abundance might impair insulin signaling.  
1.3.4 Circadian clock, diurnal rhythm and adipose tissue function 
There is growing evidence that the circadian clock controls adipose tissue development and 
endocrine function [66, 67, 179]. Interplay between adipose tissue and the circadian clock has 
been demonstrated by the discovery of core clock gene expression in various adipose tissue 
depots [84, 180]. Clock-output manifests in rhythmic lipolytic activity and adipokine secretion 
[181, 182]. Mutations and gene polymorphism of core clock genes and ccg´s can disrupt 
physiological adipose tissue function and development. Mice lacking Bmal1 or Per2 show 
impaired adipogenesis, fatty acid oxidation and lipogenesis [67, 179]. Deletion of Clock leads to 
hyperlipidemia and hyperleptinemia, but also impairs pancreatic β-islet proliferation and insulin 
secretion [183] increasing the risk of T2DM. Epidemiological studies in humans further 
strengthened these findings. In obese humans, circulating leptin and adiponectin do not follow 
physiological 24 hour rhythms [184]. Genetic polymorphisms of different core clock genes have 
been linked to an increased risk of obesity and its comorbidities such as cardiovascular diseases 
and T2DM [185, 186]. In this context, time of food intake and time restricted feeding has been 
found to influence circadian clock-output. Intake of high-caloric food in the evening and drop of 
breakfast has been associated with increased weight gain [187]. Shift workers develop an 
increased risk of obesity and associated comorbidities [87, 188]. Studies in mouse models of 
obesity confirm these findings [189]. In adipose tissue, irregular feeding/fasting cycles result in 
changed expression patterns of lipolytic enzymes and adipokine secretion [190]. In contrast to 
time-restricted feeding, excessive or restricted caloric intake seems to affect both, the master 
circadian clock in the SCN and peripheral circadian clocks. 
In mouse models of obesity, clock gene expression is altered in the central nervous system (CNS) 
[191]. This probably affects the communication between the master circadian clock and adipose 
tissue. Nutrient sensors are attributed to play a fundamental role and might provide a 
mechanistically link between the nutritional state and the circadian clock. Studies in e.g. staggerer 
mice (Rorαsg/sg), a natural loss-of-function mutant strain of the clock gene Rorα, revealed that 
these mice are resistant to HFD-induces obesity [192, 193]. 
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1.4 Impact of the mTOR complex 2 on the cardiovascular system 
1.4.1 The mammalian target of rapamycin: an overview 
The mammalian target of rapamycin (mTOR) is an evolutionarily conserved atypical 
serine/threonine kinase integrating both intra- and extracellular signals [194]. Intensive research 
over the last two decades discovered that mTOR signaling pathways are associated with central 
cellular processes involved in energy storage and expenditure, cell growth and proliferation as 
well as cytoskeletal organization (figure 1-4-1). As the name implicates, the natural bacterial 
product rapamycin is a potent inhibitor of the mTOR kinase activity [195]. mTOR assembles in two 
functionally distinct multiprotein complexes, mTOR complex 1 (mTORC1) and complex 2 
(mTORC2) (figure 1-4-1). Common to both complexes are the catalytic subunit mTOR, mammalian 
lethal with sec-13 protein 8  (mLST8) [196, 197], DEP domain containing mTOR-interacting protein 
(DEPTOR) [198] and the TTi1/TEL2 complex (TELO2 interacting protein 1/ Telomere maintenance 
2) [199]. In contrast, the regulatory associated protein of mTOR (RAPTOR) [196] and proline-rich 
AKT substrate 40 kDa (PRAS40) [55, 69] are specific to mTORC1. mTORC2 contains the additional 
proteins rapamycin insensitive companion of TOR (RICTOR) [200], mammalian stress-activated 
map kinase interacting protein 1 (mSIN1) [201] and protein observed with RICTOR 1 and 2 
(PROTOR1/2) [202]. 
 
 
 
 
 
 
 
 
 
 
Figure 1-4-1: Structural composition, activators and cellular functions are different for mTORC1 
and mTORC2. mTORC1 can be activated by a brought range of intra- and extracellular signals. 
Activation of mTORC2 is restricted to growth factors. Proteins RAPTOR and PRAS40 are specific to 
mTORC1. mTORC2 is characterized by its essential proteins RICTOR, mSIN1 and PROTOR1/2. Acute 
rapamaycin treatment can inhibit mTORC1 activity, while mTORC2 signaling is only inhibited upon 
prolonged treatment with rapamycin. mTOR (mammalian target of rapamycin), TTi1/TEL2 (TELO2 
interacting protein 1/ Telomere maintenance 2), mLST8 (mammalian lethal with sec-13 protein 8), 
DEPTOR (DEP domain containing mTOR-interacting protein), RAPTOR (regulatory associated protein 
of mTOR), PRAS40 (proline-rich AKT substrate 40 kDa), RICTOR (rapamycin insensitive companion of 
TOR), mSIN1 (mammalian stress-activated map kinase interacting protein 1), PROTOR 1/2 (protein 
observed with RICTOR 1 and 2). Figure adapted from [203].  
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In addition, both mTOR complexes have distinct substrate specificity and cellular functions [194], 
but are also functionally interconnected with each other [204]. Rapamycin inhibits mTORC1 
activity, while mTORC2 is relatively insensitive. However, prolonged treatment with rapamycin 
has been shown to disrupt mTORC2 function [205].  
In the following section, function and signaling pathways of mTORC2 will be discussed in more 
detail.  
 
1.4.2 The mammalian target of rapamycin complex 2 
In contrast to mTORC1, which upstream regulators and downstream effectors are well 
characterized, less are known about how mTORC2 kinase activity is regulated and controls 
processes on the cellular and whole-body level [206, 207]. The absence of specific mTORC2 
inhibitors has complicated the studies of this protein complex.  
The usage of various genetic approaches uncovered that mTORC2 plays a key role in different 
cellular processes, including cell survival and proliferation as well as actin cytoskeleton 
organization [208]. mTORC2 signaling seems to be insensitive to nutrients, but is affected by 
growth factors such as insulin and insulin-like growth factor 1 (IGF-1). Mechanisms behind are not 
fully understood, but require phosphatidylinositol 3-kinase (PI3K) [209]. Several independent 
studies revealed phosphorylation of various members of the cAMP-dependent, cGMP dependent, 
protein kinase C (AGC kinase) family by mTORC2. These members include thymoma viral proto-
oncogene 1 (AKT1) [210], serum- and glucocorticoid-induced protein kinase 1 (SGK1) [211] and 
protein kinase C alpha (PKC-α) [200].  
RICTOR is essential for mTORC2 kinase function, acting as a scaffold recruiting different substrates 
to the complex [200]. Deletion of Rictor in cells has been shown to strongly impair mTORC2 kinase 
activity [206, 208]. Mouse models lacking Rictor in specific tissues such as pancreas, brain and 
adipose tissue additionally allowed the understanding of the mTORC2 signaling network and its 
contribution to tissue specific and overall body functions. Mice lacking Rictor in pancreatic β-cells 
exhibit moderate hyperglycemia and glucose intolerance [212]. These defects might be due to 
reduced β-cell mass, pancreatic insulin production and glucose-stimulated insulin secretion 
suggesting an active role of mTORC2 in maintaining β-cell proliferation in response to proliferative 
stimuli. In brain, Rictor deletion in the whole CNS results in reduction of brain mass, changed 
neuron morphology and function. As a possible consequence, motor activity is impaired in these 
mice [213]. Interestingly, Siuta et al. investigated the role of Rictor in the CNS using a slightly 
different mouse model and observed schizophrenia-associated behavior as well as changed 
neurotransmitter content in brain [214]. Cybulski et al. showed that mice lacking Rictor in 
adipocytes display increased lean mass, are slightly insulin-resistant, but exhibit no alterations in 
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adipogenesis and fat mass [215]. This phenotype is possible due to an increase in IGF-1 and insulin 
production. Interestingly, these knockout mice accumulate less overall fat mass upon HFD feeding 
compared with control mice fed with the same diet. Taken together, these studies strongly 
implicate an active role of RICTOR and/or mTORC2 in regulating adipose tissue function.  
 
1.4.3 Implication of mTOR in the cardiovascular system 
Although mTORC2 is a regulator of cellular and metabolic processes, its role in the cardiovascular 
system is poorly understood.  
Both, RICTOR and mTOR are necessary for cardiovascular development during mouse 
embryogenesis. Embryos with full body knockout of Rictor exhibit impaired vascular system 
formation and die at embryonic day E10.5 [216, 217]. Interestingly, deletion of Rictor in heart 
(RictorαMhc-Cre) has no effect on postnatal heart functions, while its deletion in embryonic heart 
tissue (RictorMesp1-Cre) causes heart failure and embryonic lethality [218]. Constitutive deletion of 
mTor in cardiomyocytes (c-mTORα-MhcKO) causes embryonic lethality at embryonic day E13.5 [219]. 
In these embryos, the cardiomyocyte number is significantly reduced resulting in cardiac dilation 
and dysfunction. Similar to c-mTORα-MhcKO mice, tamoxifen-induced cardiomyocyte-specific 
deletion of mTor in adult mice promotes cardiac dilation and heart failure [220]. Mice suffer from 
mitochondrial dysfunction of cardiomyocytes, which are subjected to increased fibrosis and 
apoptosis. Mice die after a couple of weeks after tamoxifen injections. Thus, data indicate that 
mTOR is not only necessary for normal cardiac development during embryogenesis, but also 
maintain cardiac function and metabolism in adult mice.  
Studies published accomplishing the role of mTORC2 on cardiac and vascular function in stressed 
and unstressed situations are sparse. Yano et al. uncovered a cardioprotective role of mTORC2 in 
ischemic preconditioned mouse hearts [221] as inhibition of both mTOR complexes, but not 
mTORC1 alone, attenuated mTORC2 protective effects. 
In mice with experimentally induced myocardial infarction (MI), selective inhibition of mTORC2 by 
Rictor knockdown enhances ischemic damage [222]. Increased cardiomyocyte fibrosis and cell 
death in these mice indicate a beneficial role of mTORC2 in cardiomyocyte survival and adaptive 
stress response after MI. Interestingly, in the same study, evidence was provided that balanced 
mTORC1 and mTORC2 signaling is crucial for cardiomyocyte stress response after MI. Cardiac 
overexpression of PRAS40, an essential component of mTORC1, inhibits mTORC1 signaling, while 
protective mTORC2-mediated AKT phosphorylation at Ser473 (pAKTSer473) was enhanced, 
improving cardiac function after MI.  
A study performed in our laboratory from Bhattacharya et al. demonstrated that mTORC2 in PVAT 
is a novel regulator of the reactivity of the thoracic aorta in mice [223]. Analysis of thoracic aortas 
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with and without PVAT revealed increased vasoconstriction and impaired vasodilation in response 
to phenylephrine. We demonstrated an up-regulation of pro-inflammatory molecule expression in 
thoracic PVAT including IL-6, TNF-α and iNOS without changed macrophage content. Thus, 
impaired mTORC2 function in PVAT diminishes PVAT vasodilatory properties affecting vascular 
reactivity of the thoracic aorta.  
Collectively, although only limited information is available on cardiac and vascular mTORC2 
function, previous reports suggest a beneficial role of mTORC2 in unstressed and stressed 
conditions. To better understand the role of mTORC2 in the cardiovascular system, knockout or 
transgenic animal models targeting specifically cells of the vascular wall are required.  
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1.5 Aim of the study 
Intensive research over the last 10 years has increased our knowledge on perivascular adipose 
tissue (PVAT) function and its interaction with the underlying blood vessel. Complex mechanisms 
regulate PVAT properties. If deregulated, PVAT properties contribute to the impairment of 
adjacent blood vessel reactivity as observed in hypertension and obesity. Despite of all efforts, a 
question that remains to be addressed is which signaling pathways contribute to changes in PVAT 
function in hypertension and other pathophysiological conditions. Recently, we identified 
mTORC2 as a novel regulator of vascular reactivity as vasoconstriction was increased and 
vasodilation impaired using mice lacking Rictor in adipocytes generated by crossing Rictorfl/fl mice 
with aP2-CRE transgenic mice (RictoraP2KO). Thoracic PVAT properties changed to a more pro-
inflammatory state as showed by increased pro-inflammatory molecules expression. Inhibition of 
iNOS normalized vascular function. However, nothing is known about the mTORC2 signaling 
network in PVAT and how impaired mTORC2 functions contribute to altered PVAT properties. 
 
Three main objectives of the study presented here were: 
 
(1) To investigate daily blood pressure and locomotor activity regulation in RictoraP2KO and 
control mice by recording hemodynamic parameters using a radiotelemetric approach. 
 
(2) To identify and characterize RICTOR-associated signaling pathways in PVAT involved in 
functionality of PVAT using a micro array. This approach allows analyzing mRNA 
expression of the whole genome. 
 
(3) To investigate the impact of iNOS inhibition on blood pressure using subcutaneously 
implanted mini pumps emitting the iNOS-specific inhibitor 1400W or saline as solvent 
control. 
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2. Results 
2.1 Part I 
DELETION OF RICTOR IN BRAIN AND FAT ALTERS PERIPHERAL CLOCK GENE EXPRESSION AND 
INCREASES BLOOD PRESSURE  
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2.1.1 Abstract 
The mammalian target of rapamycin complex 2 (mTORC2) contains the essential protein RICTOR 
and is activated by growth factors. mTORC2 in adipose tissue contributes to the regulation of 
glucose and lipid metabolism. In the perivascular adipose tissue mTORC2 ensures normal vascular 
reactivity by controlling expression of inflammatory molecules.  
To assess whether RICTOR/mTORC2 contributes to blood pressure regulation, we applied a 
radiotelemetry approach in control and Rictor knockout (RictoraP2KO) mice generated by using 
adipocyte protein-2 gene promoter-driven CRE recombinase expression to delete Rictor. 24 hour 
mean arterial pressure was increased in RictoraP2KO mice, and the physiologic decline in mean 
arterial pressure during the dark period was impaired. In parallel, heart rate and locomotor 
activity were elevated during the dark period with a pattern similar to blood pressure changes. 
This phenotype was associated with mild cardiomyocyte hypertrophy, decreased cardiac 
natriuretic peptides and their receptor expression in adipocytes. Moreover, clock gene expression 
was reduced or phase-shifted in PVAT. No differences in clock gene expression were observed in 
the master clock suprachiasmatic nucleus, though Rictor gene expression was also lower in brain 
of RictoraP2KO mice.  
Thus, the present study highlights the importance of RICTOR/mTORC2 for interactions between 
vasculature, adipocytes and brain to tune physiological outcomes such as blood pressure and 
locomotor activity.  
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2.1.2 Introduction 
The serine/ threonine kinase mammalian target of rapamycin (mTOR) is ubiquitously expressed 
and exists in 2 multi-protein complexes, mTOR complex 1 (mTORC1) and complex 2 (mTORC2) 1,2. 
The rapamycin-insensitive companion of mTOR (RICTOR) is essential for the role of mTORC2 in 
propagating phosphoinositid-3-kinase elicited signals originating from hormones and growth 
factors 2, 3. mTORC2 phosphorylates and activates members of the AGC kinase family such as AKT 
4. Adipocyte-specific ablation of Rictor results in higher lean mass due to increased levels of insulin 
and insulin-like growth factor (IGF-1), enhanced glucose metabolism and insulin resistance in mice 
5, 6. Using this mouse model we have recently shown that vascular reactivity of the thoracic aorta 
with perivascular adipose tissue (PVAT) is altered and levels of inflammatory molecules in the 
PVAT are elevated 7. However, the specificity of adipocyte protein-2 (aP2) gene promoter-driven 
CRE recombinase expression for adipose tissue, an approach which was used for all above 
mentioned studies, may vary and affect other tissues 8. Consequently, target gene expression data 
from different organs should be considered for interpretation. In the present study we refer to 
these mice as RictoraP2KO mice.  
In a healthy condition, PVAT releases vasoactive molecules conferring anti-contractile properties 
to PVAT 9. In obesity, PVAT’s secretory profile changes to favor a pro-inflammatory state 
compromising PVAT’s anti-contractile properties 10. Impaired PVAT function contributes to 
alterations in vascular reactivity which manifests itself in blood pressure changes as observed 
previously in a rat model of hypertension 11. Intriguingly, inflammation is present in the 
vasculature in animal models of hypertension 12, 13, which supports the idea that inflammation of 
PVAT might play a significant role in the development of hypertension. The key characteristics of 
essential hypertension are hyperactivation of the renin-angiotensin aldosterone system and the 
sympathetic nervous system 14. These 2 systems are also under the control of the circadian clock 
15, which is not surprising considering the diurnal fluctuations in blood pressure. Clock genes are 
part of a hierarchically organized circadian clock system in which the suprachiasmatic nucleus 
(SCN) in the hypothalamus serves as a master clock 16. The SCN is entrained by the light/dark cycle 
and transmits humoral and neural signals to synchronize peripheral clocks located in most tissues, 
including the heart, adipose tissue and blood vessels 15.  
In the present study, we examined whether the increase in aortic contractility due to impaired 
PVAT function, which we reported previously, translates into elevated blood pressure.  
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2.1.3 Results  
2.1.3.1 Mean arterial pressure is increased and its physiological decline nearly absent in Rictor
aP2KO 
mice 
To investigate whether the increased aortic contractility which we observed previously in 
Rictor
aP2KO mice 7 translates into higher blood pressure, hemodynamic parameters were recorded 
using radiotelemetry. The 24 hour average of mean arterial pressure (MAP, Figure 1B, left panel 
and table S1) and diastolic arterial pressure (DAP, Table S1) were increased in RictoraP2KO mice 
(+5.4mmHg and +4.4mmHg, respectively; P<0.05), while systolic arterial pressure (SAP) displayed 
an upward trend (P=0.08, Table S1) compared with control mice. Pulse pressure was similar 
between groups (Table S1). To determine diurnal patterns of MAP in RictoraP2KO and control mice, 
we analyzed data obtained from a telemetric measurement over 7 days. Both groups displayed 
diurnal rhythmicity of MAP (Figure 1A, left panel). A detailed analysis for day five is shown in 
Figure 1A (right panel). However, the physiological decline of MAP in RictoraP2KO mice during the 
second half of the dark period appeared to be nearly absent (Figure 1A). Therefore, we analyzed 
MAP during the first and second half of the dark period separately. MAP was not significantly 
different during the first half of the dark period (Figure 1B, grey shaded area). While decreasing 
significantly during the second half only in controls (P<0.05), MAP remained high in RictoraP2KO 
mice (Figure 1B, grey shaded area). The Pearson correlation coefficient between time and MAP 
values during the second half of the dark period for control and RictoraP2KO mice had median 
values of -0.3 and 0, respectively (Figure 1C). This suggests that the decline in MAP during the 
second half of the dark period is nearly absent in RictoraP2KO mice. In the first half of the light 
period, MAP values were different between groups (P<0.05), while MAP levels were similar in the 
second half, showing a steady increase with highest values at the transition to the dark period 
(ZT12/ 7pm; Figure 1B). A detailed analysis of the DAP, SAP, and heart rate (HR) for day five 
revealed that these blood pressure parameters followed similar patterns as MAP (Figure 1D).  
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Figure 1: Mean arterial pressure is increased and its physiological decline is strongly impaired in 
Rictor
aP2KO
 mice. (A, left panel) Diurnal fluctuations of MAP are represented as 1 hour running median 
in Rictor
aP2KO
 and control mice. The 12:12 hour light/dark cycle is schematically depicted as white and 
black bars, respectively (light was switched on at Zeitgeber time (ZT) 0: 7 am; light off: 7 pm/ ZT12). (A, 
right panel) MAP values are represented as hourly means ± SEM for day five. The grey shaded area 
denotes the dark period. (B) MAP measurements were analyzed during 24 hours, for the first and 
second half of the light and dark periods, separately. The median is indicated as a horizontal line. (C) 
MAP drops in control, but not in Rictor
aP2KO
 mice during the 2
nd
 half relative to the 1
st
 half of the dark 
period. (D) Diastolic and systolic arterial pressure and heart rate were analyzed in the conditions 
outlined in A. n=5/6. *P<0.05, **P<0.01 vs control. ns indicates nonsignificant.  
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2.1.3.2 Impaired decline of locomotor activity during the dark period and overall hyperactivity in 
Rictor
aP2KO
 mice   
Locomotor activity is an important parameter that could account for the observed changes in 
blood pressure regulation 17. In both mouse groups, the intensity of locomotor activity followed a 
diurnal pattern (Figure 2A). In control mice, locomotor activity peaked at the beginning of the 
dark period and gradually decreased as the dark period progressed. During the light period, only 
low activity was observed (Figure 2A, upper panel) in these mice. Interestingly, in the second half 
of the dark period, RictoraP2KO mice had a tendency to maintain high locomotor activity (Figure 2A, 
lower panel, red shaded areas: 1:00 to 7:00 am), which appeared to continue intermittently as 
indicated by the spikes during the light period (Figure 2A, lower panel). A detailed analysis for day 
5 is shown in Figure 2B. Next, we quantified overall activity data collected during the telemetric 
measurements. During the light and dark periods, RictoraP2KO mice displayed a strong trend 
towards higher intensity of activity (light, P=0.082; dark, P=0.18, Table S2). Interestingly, the 
percentage of time during which mice show activity 17, an alternative measure for locomotor 
activity, was increased in RictoraP2KO mice compared with controls during a 24 hour cycle (Figure 
2D, Table S2). Analyzing the light and the dark periods separately, we observed a significant 
increase in the time during which RictoraP2KO mice show activity compared with controls (Table 
S2). During the dark period this increase was remarkably more pronounced.  
Differences in HR during the dark period amounted to +50 and +19 BMP per minute during light 
period in RictoraP2KO mice compared with controls (Table S1, P<0.05). Similarly to MAP, HR 
remained high during the progression of the dark period (Figure S1). To visualize the similar 
patterns of MAP, HR and locomotor activity during the dark period, these parameters were 
plotted in a single diagram displaying intensity of activity and MAP or HR, using two different y- 
axes (Supplemental Figure S2A and B). The curves for the intensity of activity were highly similar 
to those for MAP and HR within the groups.  
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Figure 2: Intensity of activity and active time are increased in Rictor
aP2KO
 mice. (A) Values plotted 
represent the 1 hour running median of the intensity of activity for control and Rictor
aP2KO 
mice. 
The black bars at the bottom indicate the 12 hour dark period and the red and green shaded areas 
correspond to the second half of the dark period in Rictor
aP2KO
 (lower panel) and control (uppe 
panel), respectively. (B) Measurements were analyzed during 24 hour on day five. The grey shaded 
area indicates the dark period. Values are means ± SEM. (C) Intensity of activity and (D) active time 
during a 24 hour cycle are represented. The median for each group is indicated as a horizontal line. 
n=5/6. *P<0.05 vs control.  
2.1.3.3 aP2 promoter-driven CRE expression ablates Rictor in adipocytes and brain  
To confirm deletion of Rictor in adipocytes in our current set of RictoraP2KO mice, we measured 
mRNA expression levels in PVAT using quantitative real time-PCR. Steady state mRNA expression 
levels of Rictor were reduced by 59% in PVAT, while they were similar in the aortic tissue between 
mouse groups (Figure 3A). As adipose tissue consists not only of adipocytes, but also other cells 
referred to as stromal vascular fraction (SVF), we separated adipocytes from SVF. In adipocytes 
from epididymal adipose tissue (EFAT) of RictoraP2KO mice, Rictor expression was decreased by 
58%, while similar levels were measured in control and knockout SVFs (Figure 3A). Further 
analysis of Rictor mRNA expression levels revealed no differences in the heart, kidney, liver, 
monocytes and T cells between groups (Figure 3A). Interestingly, Rictor mRNA levels were 
decreased in the brain (SCN by 76%; cortex by 66%, Figure 3A). Collectively, these data suggest 
that Rictor is specifically ablated in the adipocytes and brain, while SVF and aortic tissue were not 
affected.   
Results 
35 
 
We further characterized the impact of Rictor deletion in PVAT and brain. Histological 
examination of cross sections of thoracic aortas with PVAT revealed higher perivascular cell 
density in RictoraP2KO mice compared with controls (Figure 3B, right panel). Consistently, the 
number of nuclei was 57% higher in PVAT from RictoraP2KO mice (P<0.01, Figure 3B). Brains of 
Rictor
aP2KO mice appeared smaller (Figure 3C, left panel) and absolute brain weight was decreased 
by 17% compared with controls (Figure 3C, right panel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: aP2/CRE-driven deletion of Rictor decreases expression of Rictor in adipocytes and brain. 
(A) Steady state mRNA expression levels of Rictor were determined using qRT-PCR in Rictor
aP2KO
 and 
control mice. Values are expressed in arbitrary units (AU). PVAT: n=8, aortas: n=7/8, EFAT: n=8/9, 
adipocyte fraction (AF): n=7/11, stromal vascular fraction (SVF): n=4, T cells and monocytes: n=2/4, 
heart and kidney: n=7/8, liver: n=3, SCN (suprachiasmatic nucleus): n=3/5 and cortex: n=3/5. (B) 
Cross sections of thoracic aortas with PVAT from control and Rictor
aP2KO
 mice stained with 
haematoxylin/eosin (upper panel; black bar: 100 µm), and Hoechst (lower panel; white bar: 50 µm). 
Arrowheads indicate the thoracic aorta. Cell density of the perivascular tissue was determined by 
counting Hoechst-stained nuclei (n=5). (C) Representative photographs of brains and quantification 
of absolute brain weight from each genotype (n=7/8). Values are means ± SEM. **P<0.01, 
***P<0.005, and ****P<0.001 vs control. 
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2.1.3.4 Evidence of mild cardiomyocyte hypertrophy in Rictor
aP2KO 
mice 
Next, we carried out morphological assessment of the heart to evaluate the presence of possible 
hypertrophic changes. Mean absolute heart weights were higher in RictoraP2KO mice (Figure 4A), 
while mean relative to body heart weights were not changed compared with controls (Figure 4A). 
Right ventricular free wall and interventricular septal thickness was increased in RictoraP2KO mice 
(P=0.09 and P=0.08, respectively, Figure 4A). The hearts of RictoraP2KO mice exhibited histological 
changes consistent with mild cardiomyocyte hypertrophy, as indicated by a 25% increase in the 
cardiomyocyte cross-sectional area (Figure 4B, P<0.01). Staining with Masson’s trichrome 
revealed no evidence of fibrosis in the myocardium (data not shown). As it has been shown that 
Rictor
aP2KO mice exhibit increased organ size 5, we suspect that increased absolute heart weights 
and mild enlargement of the cardiomyofibres are most likely due to the overall phenotype, rather 
than to a compensatory change secondary to the only mild increase in blood pressure. In addition, 
there were no findings consistent with vascular remodeling secondary to hypertension 18, such as 
narrowing of the lumen, medial hypertrophy or increased adventitial fibrosis in the aorta or in the 
renal and pulmonary small and large arteries of RictoraP2KO mice (Supplemental Figure S3 and data 
not shown). Representative cross sections of heart, kidney and aortic arch are shown in 
supplemental figure S3. Interestingly, gene expression levels of cardiac hypertrophy biomarkers 
were decreased in the heart of RictoraP2KO mice: Atrial natriuretic peptide (Anp) was decreased by 
52% (P<0.05), while brain NP (Bnp) and β-myosin heavy chain (β-Mhc) showed a strong 
downwards trend (Figure 4C, left panel). The natriuretic peptides (NPs) bind to the 
transmembrane high affinity NP receptors NPR1, NPR2 and NPR3 19. These receptors are 
expressed in adipocytes to regulate adipose tissue metabolism including lipolysis and adipokine 
secretion 19. Npr2 and Npr3 mRNA expression levels were decreased in adipocytes isolated from 
EFAT by 51% and 45%, respectively (Figure 4C, middle panel). A similar expression pattern of NP 
receptors was measured in PVAT (Figure 4C, right panel). In contrast, the Anp gene expression 
was nearly absent in PVAT. 
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Figure 4: Mild cardiomyocyte hypertrophy and decreased gene expression of natriuretic peptides 
and their receptors in Rictor
aP2KO 
mice. (A) Quantification of total heart weight, heart weight relative 
to body weight, LV, RV and IVS thickness. n=7/8. (B) Representative images of heart tissue stained 
with Periodic acid-Schiff reaction (white bar: 50 µm) and quantification of cardiomyocyte area. (C) 
Steady-state mRNA expression levels of indicated genes were determined in heart (left panel, 
n=7/8), in adipocytes from EFAT (middle panel, n=6/7), and in PVAT (right panel, n=3) using qRT-PCR. 
Values are expressed in arbitrary units (AU). *P<0.05 and **P<0.01 vs control. IVS (interventricular 
septum), LV (left ventricle), RV (right ventricle). Anp indicates atrial natriuretic peptide; Bnp, brain 
natriuretic peptide; Cnp, C-type natriuretic peptide; Mhc, myosin heavy chain; and Npr, natriuretic 
peptide receptor. 
2.1.3.5 Higher insulin levels and variations in Rictor
aP2KO
 mice 
In previous studies using aP2 gene promoter-driven CRE-recombinase to knockout Rictor in mice 5, 
6, diurnal fluctuations of insulin were not investigated. Therefore, we measured insulin levels 
every 4 hours during a 24 hour cycle (Figure S4A). Insulin levels were higher at the beginning of 
the light period at ZT2 (9am), and a trend towards higher insulin levels could also be observed 
during the dark period at ZT14 (9pm) and ZT18 (1am) (Figure S4A). Overall, levels of insulin varied 
7.6-fold during a 24 hour cycle while in controls only a 1.6-fold variation was quantified (Figure 
S4A). Glucose levels in plasma were significantly higher at the end of the light period (ZT10; 5pm) 
Results 
38 
 
followed by a sharp decline at ZT14 in RictoraP2KO mice, indicating that higher insulin levels might 
lead to decreased glucose plasma levels at the beginning of the dark period. (Figure S4B).  
2.1.3.6 Identification of differentially expressed genes in PVAT of Rictor
aP2KO
 mice 
Data from blood pressure and locomotor activity analyses revealed a complex phenotype in the 
Rictor
aP2KO mice which could not be explained solely by the induction of pro-inflammatory 
molecule expression in PVAT. To identify differentially expressed genes in PVAT of RictoraP2KO 
mice, we performed a micro array analysis. Gene Ontology analysis of differentially expressed 
genes (Table S4) revealed the circadian rhythm as the most affected pathway in PVAT (Table S3). 
The data have been deposited in GEO database (Accession Number: GSE67077). 
2.1.3.7 Divergent clock gene expression in perivascular adipose tissue, but not in the 
suprachiasmatic nucleus, in Rictor
aP2KO
 mice  
To further examine the impact of Rictor deletion on clock genes, we analyzed mRNA expression 
levels of core clock genes Bmal1, Clock, Npas2, Cry1/2, Per1/2, Rev-Erb-alpha (Rev-Erb-α) and 
Rorα over a 24 hour cycle in PVAT and in aortic tissue (Figure 5 and supplemental figure S5, 
respectively). In aortic tissue, mRNA expression levels were mostly comparable between mouse 
groups and followed similar diurnal patterns (Figure S5). In PVAT, expression of Clock, Cry1, Per1, 
and Rorα was lower only during the light period in RictoraP2KO mice compared with controls (Figure 
5). For Per2, a phase-shift at the transition from the light to the dark periods was observed. 
Collectively, these data suggest that ablation of Rictor in adipocytes strongly impacts clock gene 
expression in PVAT, but has only minimal effects on these genes in the aortic tissue.   
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Figure 5: Steady state mRNA expression levels of core clock genes are different in perivascular 
adipose tissue (PVAT) of Rictor knockout (Rictor
aP2KO
) mice during the light period. mRNA 
expression levels of core clock genes in PVAT were determined using qRT-PCR. Grey shaded areas 
represent the 12 hour dark period. Values are expressed in arbitrary units (AU). n=3 per group and 
time point. *P<0.05, **P<0.01, ***P<0.005, #P=0.06 and §P=0.08 vs control.  
We found that the circadian rhythm of blood pressure (Figure 1) and locomotor activity (Figure 2) 
is altered in RictoraP2KO mice. Thus, we quantified clock gene expression in the SCN during a 24 
hour cycle. No differences in the mRNA expression levels of Bmal1, Npas2, Clock, Cry1/2, Per1/2, 
Rev-Erb-α and Rorα were detected between mouse groups (Figure 6). Collectively, these findings 
indicate that decreased Rictor expression in the SCN does not affect core clock gene expression, 
while expressional changes of Clock, Rorα, Per1/2, and Cry1 in PVAT are likely to contribute to 
increased blood pressure observed in RictoraP2KO mice.  
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Figure 6: Deletion of Rictor does not affect core clock gene expression in the suprachiasmatic 
nucleus. mRNA expression levels of core clock genes in the suprachiasmatic nucleus (SCN) of 
Rictor
aP2KO 
and control mice were analyzed using qRT-PCR. Grey shaded areas represent the 12 hour 
dark period. Values are expressed in arbitrary units (AU). n=3/5 per group and time point.  
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2.1.4 Discussion 
This is the first study to show that RICTOR/mTORC2 acts as a regulator for coordinated diurnal 
expression of clock genes in PVAT, but not in the SCN. At the whole body level, RICTOR/mTORC2 
in adipose and brain tissue contributes to the diurnal regulation of blood pressure and locomotor 
activity. The presented data demonstrate the importance of the mTORC2 signaling pathway in the 
brain to adipocyte axis for daily fluctuations of physiological processes.  
We and others have recently shown that mTORC2 activity controls inflammatory molecule 
expression using tissue-specific Rictor knockout mouse models 
7, 20
. We showed that vascular 
contractility in Rictor
aP2KO
 mice is increased due to enhanced secretion of pro-inflammatory 
cytokines in PVAT 
7
. Ablation of Rictor strongly reduced AKT
Ser473
 phosphorylation, resulting in 
impaired mTORC2 signaling 
5-7
. Consequently, we assign the observed changes in Rictor
aP2KO
 mice 
to the impaired mTORC2 downstream signaling. 
In the present study, we explored these findings further by studying blood pressure regulation in 
Rictor
aP2KO
 mice. In line with our hypothesis, Rictor
aP2KO
 mice showed increased MAP and 
alterations of its diurnal patterns. The increase in blood pressure parameters was too small to be 
considered as hypertension. In fact, our observations rather point towards a phenotype in 
Rictor
aP2KO
 mice which is termed pre-hypertension in patients 
21
. The term pre-hypertension is 
defined as blood pressure levels of 120-139 mmHg for systolic and 80-89 mmHg for diastolic 
blood pressure, respectively 
21
. Applying this definition to mice, we established a pre-hypertensive 
phenotype in the Rictor
aP2KO
 mice. At the tissue level, we found that cell density of thoracic PVAT, 
shown to be highly similar to brown adipose tissue (BAT) 
22
, is increased in Rictor
aP2KO
 mice. 
Intriguingly, it has been demonstrated that perivascular cell density is increased in an animal 
model of hypertension 
11
, and that adipocytes in BAT lacking Rictor are smaller 
23
. This led us to 
speculate that elevated blood pressure is at least partially linked to the higher cell density in PVAT 
of Rictor
aP2KO
 mice.  
NPs are hormonal regulators of vasodilation and natriuresis lowering blood pressure 
24
. We report 
that Anp and Bnp mRNA expression levels are reduced in hearts of Rictor
aP2KO
 mice. Our results 
obtained in mice are in agreement with the findings in a study with patients showing that a pre-
hypertensive state is associated with a deficiency of circulating BNP levels 
25
. Interestingly, low 
plasma levels of NPs have been identified as a common predisposition for metabolic and 
cardiovascular diseases 
19
. In line with data from hyperinsulinemic rats displaying a hypertensive 
phenotype 
26
, we showed that in Rictor
aP2KO
 mice hyperinsulinemia is associated with increased 
heart rate and blood pressure. Thus, high levels of insulin and its strong variability during the 
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course of the day might disable appropriate diurnal blood pressure regulation and/or reduce 
expression of Anp and Bnp in Rictor
aP2KO
 mice. Studying other pathophysiological mechanisms of 
hypertension 
27
, such as the activation of the renin-angiotensin-aldosterone system and the 
sympathetic nervous system, and changes in salt sensitivity was beyond the scope of the present 
study. Particularly, the possible impact of angiotensin II (ANG II) on the regulation of insulin-
dependent AKT activation warrants further investigation as ANG II plays a major role in the 
pathogenesis of insulin resistance and in the diurnal regulation of blood pressure 
28
. We focused 
on locomotor activity, another important factor that can influence heart rate and blood pressure 
17
. Locomotor activity was sustained and high in Rictor
aP2KO 
mice during the dark period, which 
could explain in part the strong impairment of the physiological decline of MAP in Rictor
aP2KO
 mice.  
We also investigated the deletion of Rictor in different organs in more detail, based on the fact 
that the tissue-specificity of the aP2 gene promoter employed to produce the conditional 
knockout may not be restricted to adipocytes 
8, 29
. Interestingly, activity of the aP2 promoter-
driven CRE recombinase in the brain was established 
8, 29
 and confirmed by our data. Using the 
brain-specific nestin promoter to drive CRE expression in floxed Rictor mice, Thomanetz et al. 
demonstrated that brain size was reduced by about 40% compared with controls 
30
. We found a 
17% reduction in brain size in Rictor
aP2KO
 mice, indicating that different approaches to target Rictor 
in the brain may result in brain size reduction of variable magnitude 
30
. The current approach to 
knockout Rictor resulted in a 50-75% reduction of Rictor gene expression in adipose tissues and 
brain. Therefore, we considered a potential impact of Rictor deletion in the brain, particularly in 
the SCN where the biological master clock is located, to alternatively explain the observed 
changes in daily rhythmicity of blood pressure and locomotor activity in Rictor
aP2KO
 mice. Tightly 
regulated clock genes control daytime-dependent behaviors and mammalian physiology 
31
. 
Mutations and deletions of clock genes in mice have been associated with changes in blood 
pressure and/or its diurnal patterns 
32
. In the SCN, diurnal expression of core clock genes 
remained unaltered during the 24 hour cycle. These results imply that changes in blood pressure 
and locomotor activity observed in Rictor
aP2KO
 mice are regulated downstream or independently 
of the molecular clock mechanism in the SCN. Thus, the present data underpins the importance of 
the exact tuning of Rictor expression in the brain-adipose axis to ensure daily oscillation of 
physiological processes. The impact of Rictor deletion in other brain regions possibly influencing 
the observed phenotype of Rictor
aP2KO
 mice needs further investigation.  
In contrast, genome wide mRNA expression analysis revealed a significant impact of Rictor 
deletion on peripheral clock gene expression in PVAT. Further analysis over a 24 hour cycle 
revealed significantly reduced expression of clock genes Rorα, Per1, Cry1 and Clock and Per2 
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phase-shift in PVAT of Rictor
aP2KO
 mice. Interestingly, Rorα and Per1/Per2 have been shown to 
contribute to the regulation of inflammatory processes in the cardiovascular system 
33
 and in the 
adipose tissue 
34
. Decreased expression of Per1/2, Cry1 and Clock was shown in inflamed EFAT of 
genetically obese ob/ob mice 
34
. Thus, reduced Rorα, Per1, Cry1 and Clock gene expression might 
facilitate the pro-inflammatory molecule expression in Rictor
aP2KO
 mice which we observed 
previously 
7
 and increase in blood pressure.  
2.1.5 Perspectives 
In summary, the present study establishes the importance of RICTOR/mTORC2 in the regulation of 
the interactions between vasculature, adipocytes and brain to tune oscillatory physiological 
outcomes such as blood pressure and locomotion. These interactions are likely to be mediated by 
hormones such as insulin and natriuretic peptides. Further experiments are needed to elucidate 
these complex relationships which might give hints for effective strategies to combat pre-
hypertensive conditions in patients. 
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Novelty and Significance 
What is New? 
- RICTOR in adipose tissue and brain contributes to the regulation of blood pressure and 
locomotion.        
- RICTOR stabilizes diurnal fluctuations of clock gene expression and impacts cell density in 
PVAT, but has no impact on clock genes in the suprachiasmatic nucleus.  
- Gene expression of natriuretic peptides and their receptors is reduced in the heart and 
adipocytes of Rictor
aP2KO
 mice. 
What is relevant? 
- Reduced Rictor expression may be a key event during pre-hypertension in patients 
facilitating progression of the disease by increasing PVAT inflammation and by dampening 
of the protective signaling of natriuretic peptides.  
- RICTOR in the brain-adipocyte axis contributes to the regulation of fluctuating 
physiological functions such as blood pressure and locomotion. 
Summary 
At the tissue level, aP2 gene promoter driven CRE recombinase expression to ablate Rictor 
gene expression, results in a higher cell density and impaired daily fluctuations of core 
clock genes in PVAT. 
At the whole body level, RICTOR/mTORC2 in adipose tissue and brain modulates diurnal 
fluctuations in blood pressure and locomotion and results in a smaller brain. The 
underlying mechanism possibly involves impaired PVAT function, induction of 
hyperinsulinemia and reduced natriuretic peptide signaling. 
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2.1.9 Supplementary data 
Table S1: Summary of the hemodynamic parameters recorded in control and Rictor
aP2KO
 mice 
during the 12 hour light period, 12 hour dark period and the 12:12 hour light/dark cycle. Values 
represent arithmetic means ± SEM derived from 7 days of continuous measurement. n=5/6. *P<0.05 
and **P<0.01 versus control.  
 
 
Table S2: Summary of intensity of activity and percentage of active time in control and Rictor
aP2KO
 
mice during the 12 hour light period, 12 hour dark period and 12:12 hour light/dark cycle. Values 
represent arithmetic means ± SEM derived from 7 days of a continuous measurement. n=5/6. *P<0.05, 
**P<0.01 versus control. 
 
  
 
Control Rictor
aP2KO
 
 
light dark 24 hour Light dark 24 hour 
MAP, mmHg 94.4 ± 1.5 102.6 ± 1.3 98.5 ± 1.4 99.1 ± 1.0 108.7 ± 1.5* 103.9 ± 1.1* 
DAP, mmHg 86.5 ± 0.5 94.0 ± 0.7 90.2 ± 0.6 89.9 ± 1.0* 99.4 ± 2.0* 94.6 ± 1.4* 
SAP, mmHg 102.6 ± 2.7 111.4 ± 2.5 107.0 ± 2.6 107.4 ± 1.9 117.2 ± 1.7 112.3 ± 1.7 
PP, mmHg 16.1 ± 2.7 17.3 ± 2.9 16.7 ± 2.8 17.5 ± 2.2 17.8 ± 2.2 17.7 ± 2.2 
HR, BPM 400.3 ± 4.4 445.7 ± 5.0 423.0 ± 4.5 418.8 ± 11.9 495.8 ± 11.9** 457.3 ± 10.4* 
 
Control Rictor
aP2KO
 
 
light dark 24 hour light dark 24 hour 
Intensity of activity, 
counts/min 
2.0  ± 0.2 6.2 ± 0.7 4.1 ± 0.5 4.2 ± 1.1 10.5 ± 2.4 7.4 ± 1.7 
Active time, % 19.6 ± 2.3 47.1 ± 2.3 33.4 ± 2.2 33.5 ± 5.6* 68.7 ± 4.7** 51.1 ± 5.0* 
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Table S3: Gene ontology analysis of micro array data revealed a significant impact of Rictor deletion 
in adipocytes on clock gene expression in PVAT from Rictor
aP2KO
 mice.  
 
Gene ontology analysis of 68 differentially expressed genes (P<0.05; fold change > 1.5) was performed 
using GeneGo analysis program (www.genego.com). Most genes were assigned to networks involved 
in circadian rhythm, lipid synthesis/metabolism and cytoskeletal remodeling. 
  
Process  
GeneGO analysis –  
Pathways Maps 
Total-No. 
of genes 
Genes changed in 
Rictor
aP2KO
 
P-Value 
1 
Neurophysiological process –  
Circadian rhythm 
47 
Bmal1, Dec1, Cry1,  
Rev-Erbα, Npas2 
2.051E-07 
2 Cholesterol Biosynthesis 88 
Nsdhl, Cyp51A1, 
Fdps 
2.103E-03 
3 
Regulation of lipid metabolism - 
Regulation of lipid metabolism via LXR, 
NF-Y and SREBP 
38 Cyp51A1, Ldlr 5.492E-03 
4 
Protein folding and maturation - 
Angiotensin system maturation / Rodent 
version 
48 Mc-cpa, Mcpt4 8.655E-03 
5 
Development - TGF-beta receptor 
signaling 
50 Pai1, Gadd45 beta 9.366E-03 
6 
Cytoskeleton remodeling - Cytoskeleton 
remodeling 
102 Melc, Pai1 3.588E-02 
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Probe 
Name Accession Gene Symbol Gene Name 
Log2 
ratio ratio P-Value 
10404389 NM_013674 Irf4 interferon regulatory factor 4 1.469 2.768 0.02768 
10362420 NM_029726 Trdn Triadin 1.257 2.39 1.12E-05 
10345675 NM_008719 Npas2 neuronal PAS domain protein 2 1.233 2.35 0.003811 
10410388 AK149411 E430024C06Rik RIKEN cDNA E430024C06 gene 1.07 2.099 0.0008981 
10362428 NM_029726 Trdn Triadin 1.037 2.052 0.00779 
10420247 NM_010779 Mcpt4 mast cell protease 4 0.9781 1.97 0.009402 
10474972 NM_026929 Chac1 ChaC, cation transport regulator-like 1 (E. coli) 0.9555 1.939 0.03205 
10371400 NM_007771 Cry1 cryptochrome 1 (photolyase-like) 0.9347 1.911 0.02016 
10409278 NM_017373 Nfil3 nuclear factor, interleukin 3, regulated 0.8999 1.866 0.01812 
10417371 NM_001024712 NM_100042149 
Gm3696;  
Gm2897 
predicted gene 3696 
predicted gene 2897 0.7937 1.734 0.002434 
10497451 NM_007753 Cpa3 carboxypeptidase A3, mast cell 0.733 1.662 0.02231 
10516932 NM_144907 Sesn2 sestrin 2 0.7301 1.659 0.01513 
10458555 NM_011898 Spry4 sprouty homolog 4 (Drosophila) 0.6833 1.606 0.004955 
10419156 
NM_053112 
NM_007895 
NM_007894 
NM_001012766.1 
NM_017388.1 
Ear10 
Ear2 
Ear1 
Ear12 
Ear3 
eosinophil-associated, ribonuclease A 
family, member 10 
eosinophil-associated, ribonuclease A 
family, member 2 
eosinophil-associated, ribonuclease A 
family, member 1 
eosinophil-associated, ribonuclease A 
family, member 12 
eosinophil-associated, ribonuclease A 
family, member 3 
0.6264 1.544 0.03445 
10556463 NM_007489 Arntl aryl hydrocarbon receptor nuclear  
translocator-like 0.6218 1.539 0.0007209 
10542885 NM_026054 2810474O19Rik RIKEN cDNA 2810474O19 gene 0.6178 1.535 0.01522 
10552143 NM_017394  NM_001024707 
Slc7a10 
Lrp3 
solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 
10; 
low density lipoprotein receptor-
related protein 3 
0.6174 1.534 0.02518 
10436890 ENSMUST00000114029 Gm10785 predicted gene 10785 0.6097 1.526 0.0004848 
10466304 NM_172442 Dtx4 deltex 4 homolog (Drosophila) 0.6033 1.519 0.002598 
10461614 NM_028595 Ms4a6c membrane-spanning 4-domains, 
subfamily A, member 6C 0.6029 1.519 0.004982 
10399666 ENSMUST00000101538 9030624G23Ri 
RIKEN cDNA 9030624G23 gene; 
similar to development and 
differentiation enhancing  
factor 2 
0.5981 1.514 0.0001629 
10407124 ENSMUST00000099179 AI452195 expressed sequence AI452195 0.5882 1.503 0.02528 
10450784 NM_008205 H2-M9 histocompatibility 2, M region locus 9 0.585 1.5 0.02428 
Table S4: Micro Array analysis revealed 68 genes to be differentially expressed in PVAT from Rictor
aP2KO
 mice 
compared to controls. 
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Probe 
Name Accession 
Gene 
Symbol Gene Name 
Log2 
ratio ratio P-Value 
10349694 NM_178079 Pm20d1 peptidase M20 domain containing 1 -0.5872 0.6656 0.01873 
10588691 NM_008317 NM_019750.3 
Hyal1 
Nat6 
hyaluronoglucosaminidase 1 
N-acetyltransferase 6 -0.5907 0.664 0.03446 
10527920 NM_020010 Cyp51 cytochrome P450, family 51 -0.5943 0.6624 0.006773 
10499483 NM_134469 Fdps farnesyl diphosphate synthetase -0.597 0.6611 0.0005444 
10488762 NM_009228 Snta1 syntrophin, acidic 1 -0.6033 0.6582 0.0006908 
10399588 AJ005350 Zfp125 zinc finger protein 125 -0.6039 0.658 0.004791 
10441774 NM_013667 Slc22a2 solute carrier family 22 (organic 
cation transporter), member 2 -0.6118 0.6544 0.02106 
10480725 
 
BC029214 cDNA sequence BC029214 -0.6134 0.6537 0.01623 
10347224 NR_004414 Rnu2-10 Mus musculus U2 small nuclear RNA 10 (Rnu2), small nuclear RNA -0.631 0.6457 0.003555 
10379650 AF099974 Slfn3 schlafen 3 -0.631 0.6457 0.003555 
10373400 NM_172259 Myl6b myosin, light polypeptide 6B -0.6414 0.6411 0.04055 
10347222 NR_004414 Rnu2-10 Mus musculus U2 small nuclear RNA 10 (Rnu2), small nuclear RNA -0.6423 0.6407 0.004084 
10600082 NM_010941 Nsdhl NAD(P) dependent steroid dehydrogenase-like -0.6434 0.6402 0.01017 
10467319 NM_011255 Rbp4 retinol binding protein 4, plasma -0.6646 0.6309 0.03843 
10532828 NM_029956 Mmab methylmalonic aciduria (cobalamin deficiency) type B homolog (human) -0.6656 0.6304 0.03463 
10603736 NR_004414 Rnu2 U2 small nuclear RNA -0.6677 0.6295 0.007948 
10553354 NM_175272 Nav2 neuron navigator 2 -0.6863 0.6214 0.008013 
10578688 NR_004414 Rnu2 U2 small nuclear RNA -0.7014 0.615 0.007011 
10373000 NM_026858 Xrcc6bp1 XRCC6 binding protein 1 -0.7098 0.6114 0.00352 
10477649 NM_019811 Acss2 acyl-CoA synthetase short-chain family member 2 -0.7105 0.6111 0.008286 
10469151 NM_172471 Itih5 inter-alpha (globulin) inhibitor H5 -0.7122 0.6104 0.03679 
10551966 NM_001012401 Hspb6 heat shock protein, alpha-crystallin-
related, B6 -0.717 0.6084 0.005251 
10583732 NM_010700 Ldlr low density lipoprotein receptor -0.7182 0.6079 0.004846 
10540472 NM_011498 Bhlhe40 basic helix-loop-helix family, member 
e40 -0.7384 0.5994 0.04434 
10553092 NM_016974 
NM_203280 
Dbp 
Sphk2 
D site albumin promoter binding 
protein 
sphingosine kinase 2 
-0.7553 0.5924 0.0003359 
10585398 NM_177350 Gldn gliomedin -0.7827 0.5813 0.04205 
10381460 NR_004414 Rnu2 U2 small nuclear RNA -0.7874 0.5794 0.003409 
10381470 NR_004414 Rnu2 U2 small nuclear RNA -0.7874 0.5794 0.003409 
10381472 NR_004414 Rnu2 U2 small nuclear RNA -0.7874 0.5794 0.003409 
10391488 NR_004414 Rnu2 U2 small nuclear RNA -0.7874 0.5794 0.003409 
10381458 NR_004414 Rnu2 U2 small nuclear RNA -0.8027 0.5733 0.003953 
10579165 NM_007789 Ncan neurocan -0.8833 0.5421 0.02653 
10417734 NM_011584 Nr1d2 nuclear receptor subfamily 1, group 
D, member 2 -0.9939 0.5021 0.001567 
10364149 NM_009115 S100b S100 protein, beta polypeptide, neural -1 0.4999 0.01672 
10502949 ENSMUST00000083804 snoRNA snoRNA -1.067 0.4773 0.0002746 
Continued table S4: 
Results 
51 
 
Micro array was performed using cDNA transcribed from RNA of PVAT from Rictor
aP2KO
 mice and controls and Affymetrix 
Mouse Gene 1.1 ST array Strips. Expression data were analyzed with Affymetrix Power Tools v1.10.2 (Affymetrix, Santa 
Clara, CA) using the RMA algorithm. Differentially expressed genes were ranked in accordance to the fold change (P<0.05) 
in descending order. 
1 
= also known as Rev-Erbα; 
2
 = also known as Rev-Erbβ. 
 
 
  
10534667 NM_008871 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 -1.108 0.4639 0.006309 
10560481 NM_008036 Fosb FBJ osteosarcoma oncogene B -1.126 0.4582 0.001421 
10390691 NM_145434 
NM_178060  
Nr1d1 
Thra 
nuclear receptor subfamily 1, group D 
thyroid hormone receptor alpha -1.255 0.419 0.0217 
10364950 NM_008655 Gadd45b growth arrest and DNA-damage-inducible 45 beta -1.36 0.3897 0.009499 
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Figure S1: Heart rate is increased and its physiological decline during the dark period nearly absent 
in Rictor
aP2KO
 mice. Heart rate (HR) was recorded over a period of 7 consecutive days in Rictor
aP2KO
 and 
control mice (n=5/6) kept in a constant 12:12 hour light/ dark cycle (light on: 7 am/ ZT 0; light off: 7 
pm/ ZT 12). Diurnal fluctuations of HR are represented as one hour running median. Black bars at the 
bottom denote the 12 hour dark period.  
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Figure S2: Time courses of mean arterial pressure, heart rate and locomotor activity display similar 
patterns and are less steep in Rictor
aP2KO
 mice during the dark period. Intensity of activity, mean 
arterial pressure (MAP) and heart rate (HR) were recorded over a period of 7 consecutive days in 
Rictor
aP2KO 
and control mice (n=5/6) kept in constant 12:12 hour light/ dark cycles. Hourly means of the 
measured parameters at the indicated time points are represented. 
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Figure S3: aP2/CRE-driven deletion of Rictor affects cell density of aortic PVAT, while no 
differences in the heart and kidney are noted. Representative cross-sections stained with 
haematoxylin/eosin of (A) the heart, (B) the kidney, and (C) the aortic arch with PVAT are shown. 
Heart sections in A were performed at the level of the papillary muscles. Black bar: 2.5 mm. Grey 
bar: 500 µm. White bar: 500 µm. CO (cortex), ME (medulla), IVS (interventricular septum), LV (left 
ventricle), PM (papillary muscles), RV (right ventricle).  
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Figure S4: Strong variations in glucose and insulin plasma levels during a 24 hour cycle in 
Rictor
aP2KO
 mice. (A) Insulin and (B) glucose concentrations were determined in blood plasma every 4 
hour using BioPlex assay and UniCel DxC 800 System, respectively. Grey shaded areas represent the 
12 hour dark period. ZT (Zeitgeber time). Values represent mean ± SEM. n=3. *P<0.05 versus control.  
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Figure S5: Steady state mRNA expression levels of core clock genes are similar in aortic tissue from 
control and Rictor
aP2KO
 mice. mRNA expression levels of core clock genes in aortic tissue were 
determined using qRT-PCR. Grey shaded areas represent the dark period. Values are expressed in 
arbitrary units (AU). n=3 per group and time point. *P<0.05 versus control.   
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2.1.10 Material and Methods  
Mice and tissue collection 
Mice used in the present study were described in detail before 
1
. Briefly, mice with deletion of 
Rictor (Rictor
aP2KO
) were generated by crossing Rictor
fl/fl
 mice with C57BL/6J mice expressing CRE 
recombinase under the control of the adipocyte protein 2 (aP2, also known as fatty acid binding 
protein 4) gene promoter (purchased from JAX Laboratories, Bar Harbor, Maine, USA). In all 
experiments, male mice (18-23 weeks old) were used and as control group, littermates without 
the Cre transgene (Rictor
fl/fl
, termed henceforth control). 
Mice were kept in the institutional animal facilities (University of Zurich and University Hospital of 
Zurich, Switzerland) at 22 °C with a 12:12 hour light/dark cycle. Light onset was at 7 am [zeitgeber 
time (ZT) 0] and light offset was at 7 pm (ZT 12). Animals had access to standard chow (4.5 % 
calories from fat; Kliba Nafag, Kaiseraugust, Switzerland) and water ad libitum. All mice used were 
genotyped for Rictor (standard PCR) and Cre recombinase (quantitative RT-PCR) using specific 
mouse primers (Table S5) and standard protocols (JAX Laboratories, Bar Harbor, Maine, USA). 
Before sacrifice, mice were weighed and anesthetized by intraperetoneal (i.p.) injection (xylazine: 
20; ketamine: 100; and acepromazine: 3.0; in mg/kg body weight) and exsanguinated via cardiac 
puncture. Mice used for confirmation of the Rictor knockout in PVAT and aortas (aortic tissue) and 
for the genome expression study were starved overnight and sacrificed at 9 am.  
All mouse experiments described here were approved by the Kantonales Veterinaeramt of Zurich, 
Switzerland (License numbers ZH44/2011 and ZH184/2014). Therewith, the investigation 
conforms to the Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (8
th
 Edition, 2011).  
Isolation of T cells and monocytes using fluorescence activated cell sorting 
Freshly isolated spleens were passed through 70µm and 40µm cell strainers in order to obtain 
single cell suspension. Erythrocytes were depleted by 2 minute incubation in ACK buffer. Cells 
were incubated with the appropriate combination of fluorochrome-conjugated antibodies: anti-
CD4 (clone RM4-4), anti-CD11c (N418, both eBioscience), anti-I-A/I-E (2G9, BD Bioscience), anti-
CD11b (M1/70), anti-CD3 (17A2), anti-Ly6C (HK1.4, all Biolegend). CD3
+
CD4
+
 splenocytes were 
identified as CD4
+
 T lymphocytes cells and CD11b
+
CD11c
−
MHC-II
−
Ly-6C
hi
 splenocytes as 
inflammatory monocytes. Propidium iodide (PI, eBioscience) was used to exclude dead cells. Cells 
were sorted with FACSAria III (BD Bioscience). 
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Tissue collection and histological analysis 
For analysis of tissues during a 24 hour period, 3 mice from each group were sacrificed every 4 
hours and different tissues from control and Rictor
aP2KO 
mice were collected. The first mouse 
groups were sacrificed at 9 am (ZT 2), 2 hours after light onset. For tissue collection during the 
dark period, mice were euthanized under red light to ensure no disruption of the 12:12 hour 
light/dark cycle. Mice were not starved before sacrifice.  
After euthanasia, body weights were collected at necropsy to allow calculation of organ to body 
weight ratios. A complete necropsy, including a thorough external and internal gross post mortem 
examination was performed on each mouse. Heart and brain from each mouse were excised, 
dried on filter paper and weighed. Mouse heart weights were normalized to body weights 
(HW/BoW). Representative samples of all organs and tissues were harvested and fixed in 10 % 
neutral buffered formalin. 
PVAT was dissected from the thoracic aorta and aortic arch and tissues were immediately placed 
in RNAlater™ (Qiagen, Hilden, Germany) or directly snap-frozen. Blood collected during 
exsanguination was centrifuged at 8000 x g for 15 min at 4 °C, plasma in the supernatant snap-
frozen and kept with all the other collected tissues at -80 °C until further analysis. 
After routine paraffin wax embedding, sections (3-5 μm) were prepared and stained with 
haematoxylin and eosin (HE). Histological analysis was performed on the heart, aortic arch, lungs 
and kidneys. Three cross sections were obtained from each heart at standard distances from the 
apex, to visualize the left and right ventricles. The Masson’s Trichrome stain was applied for the 
visualization of collagen fibers in the heart and lungs 
2
. All slides were scanned using digital slide 
scanner NanoZoomer-XR C12000 (Hamamatsu, Japan) and images were taken using NDP.view2 
viewing software (Hamamatsu, Japan). Cross sectional lengths of the septal wall and right and left 
ventricular free walls were measured. 
Cardiomyocyte cross-sectional area was employed as index of cardiac hypertrophy. Periodic acid-
Schiff (PAS) staining on 3-5 µm heart sections was applied to better outline the cardiomyocyte 
boundaries and quantify cardiomyocyte cross-sectional area. Scanned slide images were taken as 
mentioned above. In all mice, measurements were taken from the outline of 50 randomly 
selected cardiomyocytes exhibiting a clear cross-cut nucleus. Measurements were done using 
ImageJ 1.48 software 
(http://imagej.nih.gov/ij/index.html). 
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Recording of blood pressure and locomotor activity in mice using radiofrequency transmitters 
Control and Rictor
aP2KO
 mice (n=5-6 per group) were implanted with a telemetry sender (TA11PA-
C10, Data Sciences International, St. Paul, MN, USA) via the left carotid artery to monitor 
simultaneously mean (MAP), diastolic (DAP) and systolic arterial pressure (SAP), pulse pressure, 
heart rate (HR), and locomotor activity. Operation and post-operative care procedures were 
described previously 
3
. Briefly, mice were anesthetized with isoflurane, and the telemetry sender 
implanted in the left carotid artery. The transmitter, connected with the telemetry sender via a 
small catheter, was positioned under the skin between the right front and hind limb. Mice were 
kept warm on a heating pad and monitored until fully recovered from anesthesia. After surgery, 
mice were single caged in a warming cabinet at 30 °C in a 12:12 hour light/dark cycle with access 
to food and water ad libitum. Recovery from surgery was allowed for 7 days before 
measurements were started. During measurement, mice were housed individually and the 
temperature in the warming cabinet was adjusted to 25 °C. Blood pressure and locomotor activity 
data were determined from day 8 after surgery during the following week up to three weeks post 
telemetry sender implantation. Data from each telemetry sender were transmitted to a receiver 
plate (RPC-1, Data Sciences International, St. Paul, USA) positioned below each cage and 
thereafter collected using the Dataquest A.R.T. system, version 4.2 (Data Sciences International, 
St. Paul, USA). Blood pressure was measured for 30 seconds every 5 minutes. Locomotor activity 
was recorded continuously by the frequency of movement of each animal across the cage in 
counts/min (intensity of activity). For analysis of locomotor activity, less than 0.6 counts per 
minute were considered as inactive and set to 0 for further calculations. 
RNA isolation, reverse transcription and quantitative real-time PCR  
RNA from PVAT, EFAT and adipocytes was extracted using RNeasy® lipid tissue kit, from thoracic 
aortas, and heart using RNeasy® fibrous tissue kit, from kidney, liver and stromal vascular fraction 
using RNeasy® mini kit, and T cells and monocytes using RNeasy® plus mini kit according to the 
protocol of the manufacturer (Qiagen, Hombrechtikon, Switzerland) respectively, including an on-
column DNase digestion (RNase-free DNase, Qiagen). Before reverse transcription, RNA quantity 
and quality was determined using Nanodrop 2000 Spectrophotometer and Agilent 2100 
Bioanalyzer. Reverse transcription of 50 ng RNA from PVAT, stromal vascular fraction and thoracic 
aortas was performed using WT (Whole Transcript)-Ovation® Pico RNA Amplification System 
(Nugen, Bemmel, Netherlands) and from EFAT, adipocytes, heart, kidney, liver, T cells and 
monocytes using iScript™
 
Reverse Transcription Supermix according manufactures 
recommendations (BioRad, Hercules, CA, USA). For quantitative RT-PCR, final cDNA concentration 
was adjusted to 10 ng in a 15 µl reaction volume. Each reaction was performed in duplicates using 
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Bio-Rad CFX96 Real-Time System and iQ™ SYBR
®
 Green Supermix (BioRad, Hercules, CA, USA) and 
specific mouse primers. Gene expression in PVAT, thoracic aortas, EFAT and adipocytes was 
normalized to the reference gene acidic ribosomal phosphoprotein (Arbp), in heart, kidney and 
liver to the reference gene cyclophelin B and in the stromal vascular fraction to the reference 
gene TATA box binding protein (Tbp) using the comparative C(T) method 
4
. If not otherwise noted, 
mouse primer pairs for selected genes were designed using Primer Blast (NCBI, USA) 
5
 and are 
listed in supplementary method Table S4. 
Isolation of RNA from suprachiasmatic nucleus and brain cortex 
The brain was dissected, placed in artificial cerebrospinal fluid (ACSF; NaCl - 120 mM; KCl - 2.5 
mM;  MgCl2 x 6*H2O - 1 mM; NaH2PO4 x 2*H2O; - 1.25 mM; NaHCO3 - 26 mM; HEPES - 5 mM; CaCl2 
- 2 mM; glucose - 16 mM; pH 7.35) and 250 to 300 µm brain slices were cut using a vibratom 
(Leica VT 1200, Leica Biosystems, Switzerland). Brain regions containing the SCN and cortex were 
identified under a binocular (Olympus SZ61, Volketswil, Switzerland), cut out, and stored at - 80°C 
until further analysis. SCN and cortex were homogenized in 300 µl RLT-buffer with β-
mercaptoethanol by vortexing the samples 3 x 10 sec at room temperature. RNA was extracted 
using RNeasy® micro kit according the recommendations of the manufacturer (Qiagen, 
Hombrechtikon, Switzerland). 5 µl eluat from the isolation columns were reversed transcribed to 
cDNA using WT (Whole Transcript)-Ovation Pico RNA Amplification System (Nugen, Bemmel, 
Netherlands). cDNA transcription and quantitative RT-PCR were performed as described above 
and relative gene expression levels were normalized to glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh). 
Bioplex Analysis 
Bioplex assay was performed using blood plasma collected from control and Rictor
aP2KO
 mice at ZT 
2 (9 am) and ZT 14 (9 pm). Concentrations of insulin were measured using corresponding 
components of BioPlex™ Pro Mouse Diabetes assay according to the manufactures protocol in a 
Bioplex™ 100 machine (BioRad, Hercules CA, USA). Data were analyzed using BioPlex™ Manager 
4.1.1 software and quantified based on the Logistic-5PL regression standard curve.  
Blood glucose levels 
Blood glucose levels were determined at ZT 2 (9 am) and ZT 14 (9 pm) in Rictor
aP2KO
 and control 
mice using UniCel DxC 800 System and specific reagent, calibration and control kits for glucose 
measurement (Beckman Coulter, Galway, Ireland) according manufactures recommendations.  
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Histology of thoracic aorta and PVAT 
10 µm cross sections from thoracic aortas with PVAT were cut as described previously 
6
. Prior to 
staining, slides were dried for 20 min at room temperature, fixed in 4 % PFA in PBS (pH 7.4) for 10 
minutes and washed twice for 5 min in aqua-dest. Haematoxylin staining was performed using 
Mayer’s haematoxylin (Dako, Baar, Switzerland) for 3-5 min followed by a 5 min washing step 
under slowly running tap water. For differentiation, slides were dunk twice in acidic alcohol (0.3 % 
HCl in 70 % EtOH) and washed immediately in aqua dest. For eosin staining, slides were incubated 
30 sec in 0.1 % Eosin (Sigma, Buchs, Switzerland) washed immediately in deionized water and 
differentiated in 70 % Ethanol for 3 sec. Slides were washed twice for 2 min in deionized water 
and air dried. Coverslips were mounted with Eukit quick-hardening mounting medium (Sigma, 
Buchs, Switzerland) onto slides. 
Staining of the nuclei using Hoechst: Fixed cross-sections were incubated for 60 min with blocking 
buffer (5 % goat serum in PBS / 0.1 % TWEEN). Slides were washed twice for 5 min with PBS (pH 
7.4) and nuclei were stained with Hoechst (2 µg/µL in PBS, pH 7.4, Life Technologies) for 5 min. 
Slides were washed 3 x 5 min with PBS (pH 7.4) and mounted with fluorescent mounting medium 
(Dako, Baar, Switzerland). 
Slides were dried at least 1 day before imaging. Images were acquired using CLSM Leica SP5 
microscope and LAS-AF 2.6.3.8173 software (Leica, Heerbrugg, Switzerland). Nuclei were counted 
using image J 1.48 for Windows (NIH, USA) in a 475 x 340 µm area. 
Genome Expression Study  
Total RNA was isolated from PVAT surrounding the thoracic part of the arterial tree from control 
and Rictor
aP2KO
 mice. Total RNA was extracted using the RNeasy® lipid tissue kit according 
manufactures recommendation (Qiagen, Hombrechtikon, Switzerland). DNase digestion of 
isolated total RNA was performed in solution (RNase-free DNase, Qiagen), followed by an 
additional purification step of total RNA using RNeasy® mini kit according manufactures protocol 
(Qiagen, Hombrechtikon, Switzerland). Before further analysis, RNA quality and quantity was 
determined using Nanodrop 2000 Spectrophotometer and Agilent 2100 Bioanalyzer. Only total 
RNA with an RNA integrity number (RIN) > 8 were considered for further analysis.  
Total RNA was reverse transcribed and cDNA amplified using Ambion® WT Expression kit 
(Affymetrix, United Kingdom) following manufacturer's protocols. Biotinylated cDNA was 
prepared using Encore Biotine Module (Nugen, Netherlands) according to manufacturer's 
recommendations and hybridized to Affymetrix Mouse Gene® 1.0 ST array strips (Affymetrix, 
Santa Clara, CA). Gene Chips were scanned using the Hewlett-Packard GeneArray Scanner G2500A 
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(Hewlett-Packard, Böblingen, Germany) and expression data analysed with Affymetrix Power 
Tools v1.10.2 (Affymetrix, Santa Clara, CA) using the RMA algorithm. The data discussed in this 
publication have been deposited in NCBI's Gene Expression Omnibus 
7
 and are accessible through 
GEO Series accession number GSE67077  
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?&acc=GSE67077). 
For further data analysis, genes were considered to be differentially expressed in Rictor
aP2KO
 mice 
if P<0.05 and fold change > 1.5. A gene ontology analysis was performed with genes identified 
using GeneGo Analysis program (www.genego.com).  
Statistical Analysis 
Data are expressed as means ± standard error of the mean (SEM) or as box blots in which the 
median is represented by a horizontal line. To this end, data from each mouse were compiled to 
one data point (mean) and are represented in box blots according to the mouse groups. 
Comparisons between groups for other experiments were analyzed by two-tailed Student’s t-test. 
For displaying MAP, levels of locomotor activity and heart rate over time, we used running 
medians to smooth data. Differences were considered statistically significant at values of P<0.05. 
Statistical analyses were performed using GraphPad Prism 5.04 program for Windows (GraphPad 
software, SanDiego, CA, USA) and R for Windows (R Core Team 2014). R: A language and 
environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria. 
URL http://www.R-project.org/). 
 
 
 
  
Results 
63 
 
Table S5: Primer pairs used for standard and quantitative real-time PCR. Primer pairs were designed 
using «primer blast» program (NCBI, USA) 
4
 and are specific to mouse cDNA. Sequences for primer pairs 
specific for Anp, Npra, Nprc, α-Mhc and β-Mhc were already described 
8,9 
 
Gene name Forward Primer (5'-3') Reverse Primer (5'-3') 
Anp CAC AGA TCT GAT GGA TTT CAA GA CCT CAT CTT CTA CCG GCA TC 
Arbp  AGCTGAAGCAAAGGAAGAGTCGGA  ACTTGGTTGCTTTGGCGGGATTAG 
Bhlhe40 ACG TTG AAG CAC GTG AAA GC CTT CCC GAC AAA TCA CCA GC 
Bmal1  ACT ACA GTG GCC CTT TG CAT  GCC CAA ATT CCC ACA TCT GAA G 
Bnp1 GTC TGG CCG GAC ACT CAG TGC ACT GGT GTC TTC AAC AAC 
Clock  TTA GAT CAC AGG GCA CCA CC  AGT GCT CGT GAC ATT TTG CC 
Cnp GAC ACC ACC GAA GGT CCC G CCT GGA GTC TTG TCA CCC TTT T 
Cre GCG GTC TGG CAG TAA AAA CTA TC ACC CGG CTG CTC TTA CTT CT 
Cry 1  ATG TCC CGA GTT GTA GCA GC  TGA GAG CAA TTT CCA CCG CT 
Cry 2 AGC TGA TGT GTT CCC AAG GCT CAT AAT GGC TGC ATC CCG TT 
Cyclophelin B GGT GGA GAG CAC CAA GAC AGA GCC GGA GTC GAC AAT GAT G 
Dbp GGA ACT GAA GCC TCA ACC AAT C CTC CGG CTC CAG TAC TTC TCA 
Gapdh  AAA TGG TGA AGG TCG GTG TG  GTT GAA TTT GCC GTG AGT GG 
Nfil3 GAG CAG AAC CAC GAT AAC CCA T TAC AGA CCG GAT GGA GGA GAC 
Npas2  AGA GGC AGC TTG AAC CCA AA  GAG GGG CTA GGC ACA TTG TT 
Npra CGA AGA CAA GTG CAT CCT GAG TGG AGA CAC AGT CAA CAC AGC 
Nprb ACC GGT CAC TTC AAG GGA AA GGC TCC GAT GAA GCG AGT AA 
Nprc AGC TGG CTA CAG CAA GAA GG CGG CGA TAC CTT CAA ATG TC 
Per1 CCA GAT TGG TGG AGG TTA CTG AGT GCG AGA GTC TTC TTG GAG CAG TAG 
Per2  AGA ACG CGG ATA TGT TTG CTG  ATC TAA GCC GCT GCA CAC ACT 
Rev-Erb-α  TGT CTA GAG ATG CTG TGC GTT T  AGG CTG CTC AGT TGG TTG TT 
Rictor (PCR) TTA TTA ACT GTG TGT GGG TTG CGT CTT AGT GTT GCT GTC TAG 
Rictor (qRT-PCR)  TGC GAT ATT GGC CAT AGT GA  ACC CGG CTG CTC TTA CTT CT 
Rorα GCT TCT AAA AGC AGG CTC GC GGG ACT TGA AGA CAT CGG GG 
Tbp  GAG TTG CTT GCT CTG TGC TG  CTG GCT TGT GTG GGA AAG AT 
α-Mhc CGC ATC AAG GAG CTC ACC CCT GCA GCC GCA TTA AGT 
β-Actin  CGT GCG TGA CAT CAA AGA GA  CCC AAG AAG GAA GGC TGG A 
β-Mhc CGC ATC AAG GAG CTC ACC CTG CAG CCG CAG TAG GTT 
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2.2. Part II 
2.2.1 Blood pressure and locomotor activity recordings in Rictor
aP2KO
 and control mice 
2.2.1.1 Frequency of activity in Rictor
aP2KO
 and control mice 
In addition to the intensity of activity and active time, the frequency of activity during the 12 hour 
light and 12 hour dark period was analyzed of Rictor
aP2KO
 and control mice. The frequency of 
activity was calculated based on the time period where mice were active. During both, the light 
and the dark period, the frequency of activity (15 to 40 min) showed an upward trend in 
Rictor
aP2KO
 mice compared with controls (Figure 2-2-1). During the dark period (active period of 
mice), Rictor
aP2KO
 and control mice displayed an overall increase in the frequency of activity 
compared to the light period (Figure 2-2-1 B). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2-1: Frequency of activity is increased in Rictor
aP2KO
 mice. Frequency of activity was 
calculated from locomotor activity recordings over 7 consecutive days and consecutive minute’s 
mice spent active during the (A) 12 hour light and (B) 12 hour dark period. Less than 0.6 counts per 
minute (15 min) were considered as inactivity. n = 5/6 
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2.2.2.2 Infusion of 1400W using mini pumps in Rictor
aP2KO
 and control mice 
We have previously proposed that upregulated expression of the inducible nitric oxide synthase 
(iNOS) impaired PVAT properties to control vascular reactivity in Rictor
aP2KO
 mice [223]. It is well 
known that immune responses including the release of pro-inflammatory cytokines contribute to 
increased blood pressure [224]. To investigate whether the increased iNOS expression in PVAT 
might directly augment blood pressure, we infused the specific iNOS inhibitor 1400W (10 mg/kg 
per day) or saline as solvent control subcutaneously in Rictor
aP2KO
 mice. To this end, in addition to 
the telemetry device, Alzet™ mini pumps either releasing 1400W or saline were implanted after 
completion of blood pressure baseline measurements (ten days after telemetry device 
implantation). After mini pump implantation, 1400W-infused Rictor
aP2KO
 mice needed five days to 
recover as evidenced by the normalization of the heart rate after surgery to baseline levels (Figure 
2-2-2 A). However, in saline-infused Rictor
aP2KO
 mice the heart rate did not reach baseline levels 
ten days after mini pump implantation and was significantly higher during the dark period (Figure 
2-2-2 A). As indicator for a possible blood pressure lowering effect of 1400W, the mean arterial 
pressure (MAP) was continuously monitored parallel to heart rate measurements (Figure 2-2-2 B) 
and the areas under the MAP curve (AUC) of the 1400W- and saline-infused mouse groups were 
calculated (Figure 2-2-2 C). Both, saline and 1400W infusion had no effect on MAP in Rictor
aP2KO
 
mice (Figure 2-2-2 C).  
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Figure 2-2-2: Inhibition of iNOS does not normalize mean arterial pressure in Rictor
aP2KO
 mice. (A) 
Heart rate and (B) mean arterial pressure (MAP) were constantly followed for 10 days post mini 
pump implantation (p.i.; filled with 1400W or saline) during the light (left panel) and dark period 
(right panel). Baseline measurements were set to 100 %. After mini pump implantation, MAP and 
heart rate were calculated as percentage of baseline. (C) 1400W treatment does not lower MAP in 
Rictor
aP2KO
 mice to levels recorded in controls. Areas under the curves (AUC) were calculated using 
daily means of MAP recordings from day 1 to 5 and 6 to 10 in Rictor
aP2KO 
mice during the light (left) 
and dark period (right panel). n=15 (baseline), n=7/8 (saline or 1400W treatment). The bars at the 
top indicate the 12 hour light (white) and 12 hour dark (black) period. 
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2.2.2 Cre-recombinase expression in Rictor
aP2KO
 mice 
In the present study, mice with deletion of Rictor (Rictor
aP2KO
) were generated crossing Rictor
fl/fl
 
mice with C57BL/6J mice expressing Cre recombinase under the control of the adipocyte protein 2 
(aP2) gene promoter. mRNA expression of the Cre recombinase was detected in adipocytes 
isolated from EFAT of Rictor
aP2KO
 mice (Figure 2-2-3). Further, the Cre recombinase was highly 
expressed in the stromal vascular fraction (SVF) separated from EFAT, in the heart as well as in the 
brain regions suprachiasmatic nucleus (SCN) and cortex (Figure 2-2-3). In the liver and the kidney 
Cre recombinase was not expressed.  
 
 
 
 
 
 
 
 
 
 
Figure 2-2-3: Cre-recombinase is expressed in adipocytes, but also in the stromal vascular fraction 
and non-adipose tissues. Cre-recombinase expression was analyzed in epididymal adipose tissue 
derived adipocytes (n=11), stromal vascular fraction (SVF; n=4), and further in heart (n=7), 
suprachiasmatic nuclei (SCN; n=3) and cortex (n=3) of Rictor
aP2KO
 and control mice. mRNA expression 
levels were analyzed using quantitative RT-PCR, specific mouse primers and calculated by ΔCT. 
Expression data were normalized to the housekeeping gene Arbp (adipocytes), Gapdh (SCN, cortex), 
Cyclophelin B (heart) and Tbh (SVF). Values are represented as means ± SEM. AU (arbitrary units). 
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2.2.3 Perivascular adipose tissue genome wide mRNA expression analysis in Rictor
aP2KO
 and 
control mice 
To identify differentially expressed genes in PVAT of Rictor
aP2KO
 mice compared to controls, a 
micro array analysis of the expressed PVAT genome was performed. 68 genes were differentially 
expressed in PVAT of Rictor
aP2KO
 mice. To validate the expressional changes of the 10 most 
increased and the 10 most reduced genes (see results part I, table S4), steady state mRNA 
expression levels were analyzed using quantitative real time PCR (qRT-PCR). 
Analysis of the steady state mRNA expression levels revealed a significant increase of the genes 
interferon regulatory factor 4 (Irf4, +298 %), neuronal pas domain protein 2 (Npas2, +243 %), mast 
cell protease 4 (Mcpt4, +160 %), sestrin 2 (Sesn2, +189 %) and sprouty 4 (Spry4, +311 %) in PVAT 
of Rictor
aP2KO
 mice compared to controls (Figure 2-2-4). Deletion of Rictor had no effect on triadin 
(Trdn), cryptochrome 1 (Cry1) and nuclear factor, interleukin 3 regulated (Nfil3) mRNA expression 
levels in PVAT of Rictor
aP2KO
 mice. Expression of the cation transporter regulator like-1 (Chac1) was 
not detected in PVAT of both mouse groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2-4: Validation of the 10 most increased genes identified with the micro array study 
revealed only mRNA expression levels of 4 genes to be sustainably changed in PVAT of Rictor
aP2KO
 
mice. mRNA expression levels of target genes Irf4, Trdn, Npas2, Mcpt4, Cry1, Nfil3, Sesn2 and Spry4 
were  analyzed in PVAT of Rictor
aP2KO
 mice and control littermates. mRNA expression was analyzed 
using quantitative RT-PCR and calculated using ΔCT method. Gene expression was normalized to the 
housekeeping gene Arbp. Values are represented as means ± SEM. *P<0.05 and ***P<0.005. n=6-10. 
AU (arbitrary units). 
 
In addition to the 10 most increased genes identified with genome expression analysis in PVAT of 
Rictor
aP2KO
 mice, the 10 most reduced genes were validated. Analysis of steady state mRNA 
expression levels revealed are significantly reduction of the genes serine (or cysteine) peptidase 
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inhibitor, clade E, member 1 (Serpine1; also known as Pai-1, -350 %) and S100 protein, beta 
polypeptide, neural (S100b, -229 %) in PVAT of Rictor
aP2KO
 mice (Figure 2-2-5). The genes growth 
arrest and DNA-damage-inducible 45 beta (Gadd45b), thyroid hormone receptor alpha (Thra), 
nuclear receptor subfamily 1, group D, member 1 (Nr1d1; also known as Rev-Erb-α), FBJ 
osteosarcoma oncogene B (Fosb), neurocan (Ncan), U2 small nuclear RNA 10 (Rnu2) and gliomedin 
(Gldn) were similar expressed in PVAT of both mouse groups. Expression of the nuclear receptor 
subfamily 2, group D, member 2 (Nr1d2; also known as Rev-Erb-β) was not detected in PVAT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2-5: Validation of the 10 most reduced genes identified with the micro array study 
revealed only mRNA expression levels of Serpine1 to be sustainably changed in PVAT of Rictor
aP2KO
 
mice. mRNA expression levels of target genes Gadd45b, Thra, Rev-Erb-α, Fosb, Serpine1, S100b, 
Ncan, Rnu2 and Gldn were analyzed in PVAT from Rictor
aP2KO
 mice and control littermates. mRNA 
expression was analyzed using quantitative RT-PCR and calculated by ΔCT.  Gene expression was 
normalized to the housekeeping gene Arbp. AU (arbitrary units). Values are represented as means ± 
SEM. *P<0.05. n=7-10  
 
In addition to the 20-top ranked genes, steady state mRNA expression levels of genes associated 
with the cholesterol biosynthesis and/or lipid metabolism were validated (Figure 2-2-6). qRT-PCR 
analysis revealed that the mRNA expression levels of NAD(P) dependent steroid dehydrogenase-
like (Nsdhl), farnesyl diphosphate synthetase (Fdps) and cytochrome P450, family 51, subfamily A, 
polypeptide 1 (Cyp51A1) showed a non-significant downward trend in Rictor
aP2KO
 mice.  
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To accomplish this expressional analysis, mRNA expression levels of additional genes associated 
with the cholesterol biosynthesis and/or lipid metabolism, but not found to be differentially 
expressed in the micro array were analyzed. The target genes sterol regulatory element binding 
transcription factor 1 (Srebp-1c), fatty acid synthase (Fasn), diacylglycerol O-acyltransferase 1 
(Dgat1) and perilipin1 showed a similar expression profile in PVAT between the mouse groups 
(Figure 2-2-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2-6: Deletion of Rictor did not affect mRNA expression levels of target genes in PVAT 
associated with the cholesterol biosynthesis and lipid metabolism. mRNA expression levels of 
indicated genes were analyzed in PVAT of Rictor
aP2KO
 and control mice using quantitative RT-PCR. 
Gene expression levels were calculated using the ΔCT method and normalized to the housekeeping 
gene Arbp. Values are expressed in arbitrary units (AU). Values are represented as means ± SEM. 
Nsdhl, Fdps, Cyp: n=8/9; Srebp-1c, Dgat1: n=8/10 and Fasn, Perilipin1: n=7 
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2.2.4 Fluctuating expression patterns of Rictor and mTORC2 downstream targets  
As the micro array study identified the circadian rhythm as the most affected pathway in the 
Rictor
aP2KO
 mice, I reasoned that the Rictor expression during a 24 hour period might have 
changed. To this end, steady state mRNA expression of Rictor was analyzed in the different 
adipose tissues PVAT, brown adipose tissue (BAT) and epididymal adipose tissue (EFAT) as well as 
aortic tissue and the liver of control and Rictor
aP2KO
 mice. As expected, expression of Rictor was 
significantly reduced in adipose tissues of Rictor
aP2KO
 mice, but remained unchanged in aortic 
tissue and the liver during the light and dark period (Figure 2-2-7). Surprisingly, in control mice 
(Rictor
fl/fl
) time-of-day dependent fluctuations in Rictor mRNA expression levels were detected in 
PVAT and BAT (to a lesser extent in EFAT) (Figure 2-2-7). Highest mRNA expression levels of Rictor 
were measured at the beginning of the light period and then gradually decreased. During the dark 
period, in control mice Rictor mRNA expression was significantly lower as compared to the light 
period (PVAT: -62 %, P < 0.0001; BAT: -45 %, P < 0.01). Interestingly, during the dark period mRNA 
expression levels of Rictor were similar in control and Rictor
aP2KO
 mice (Figure 2-2-7). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2-7: Rictor mRNA exhibit fluctuating expression in different adipose tissue depots, but not 
aortic tissue and liver. Rictor mRNA expression was determined in perivascular adipose tissue 
(PVAT), brown adipose tissue (BAT), epididymal fat (EFAT) and aortic tissue from control and 
Rictor
aP2KO
 mice at different zeitgeber times (ZT) over a period of 24 hours. Mice were kept under 
constant 12-hours light/ 12 hours dark period (lights on ZT 0: 7 am; light off ZT 12; 7 pm). Prior 
experiment, mice had access to water and food ad libitum. All values represent mean ± SEM, 
*P<0.05, n=3 mice per group and time point. Gray shaded areas represent the 12 hour dark period. 
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To investigate, whether the fluctuating Rictor expression translates on the protein level, protein 
expression of RICTOR was analyzed in PVAT of control mice at the beginning of the light (ZT 2) and 
the dark period (ZT 14). Indeed, RICTOR expression was significantly lower at ZT 2 as compared to 
the ZT 14 (Figure 2-2-8). 
 
 
 
 
 
Figure 2-2-8: Time-of-day dependent protein expression of RICTOR in PVAT of control mice. 
Immunoblot analysis of RICTOR expression in PVAT of control mice. Total Erk2 was used as reference 
control for protein loading. Tissue was collected at zeitgeber times (ZT) 2 and 14. Mice were not 
starved before experiment.  
The meter of the mTORC2 activity is its ability to phosphorylate downstream target proteins such 
as AKT. To examine, whether the fluctuating expression of RICTOR might affect mTORC2 activity, 
the phosphorylation of AKT at different residuals was investigated at ZT 2 and ZT 14 in control 
mice. In EFAT, basal phosphorylation of AKT at Serine 473 (pAKT
S473
) was higher at ZT 2 compared 
to ZT 14 (Figure 2-2-9 A). Stimulation with insulin (1 μmol/l) resulted in an overall increase of 
pAKT
S473 
phosphorylation at ZT 2 and ZT 14, but the phosphorylation was still lower at ZT 14. The 
phosphorylation of AKT at Thr308 (pAKT
T308
) followed a similar fluctuating pattern as observed for 
pAKT
S473
. For mTOR protein expression, no time-of-day dependent differences were detected in 
insulin-stimulated and unstimulated conditions (Figure 2-2-9 A). Total AKT (tAKT) and ERK2 were 
used as reference controls for protein loading and showed a similar expression pattern at ZT 2 and 
ZT 14. Both remained unchanged upon insulin-stimulation.  
In PVAT, the unstimulated and insulin-stimulated phosphorylation of pAKT
S473
 was similar to EFAT 
(Figure 2-2-9 B). However, the phosphorylation of pAKT
T308
 was neither different between time 
points, nor unstimulated and insulin-stimulated samples. mTOR protein was equally expressed at 
ZT 2 and ZT 14 and did not change with stimulation of insulin. The expression of the loading 
controls tAKT and ERK2 was similar between times points and groups. 
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Figure 2-2-9: Immunoblot analysis of EFAT and PVAT revealed daytime dependent 
phosphorylation of AKT at serine 473 in control mice. Immunoblot analysis of insulin-stimulated 
(A) epididymal adipose tissue (EFAT) and (B) perivascular adipose tissue in control mice are shown. 
Total AKT and ERK 2 were used as loading control. One representative blot of 2 is shown. Protein 
loading: 25 µg/ lane.  
Alongside the analysis of Rictor, 24 hour mRNA expression patterns of nutrient sensors were 
analyzed in PVAT. Nutrient sensors such as SIRT1 (Sirtuin1) and PGC-1α (Pparg co-activator 1 α) 
integrate metabolite-derived signals are believed to play a key role in the generation of daytime 
dependent cellular processes [225-227]. The expression of Sirt1, Pgc-1α, RAR-related orphan 
receptor gamma (Rorc), nuclear factor-interleukin 3-regulated (Nfil3) and D site albumin promoter 
binding protein (Dbp) fluctuated though the course of the day (Figure 2-2-10). In Rictor
aP2KO
 mice, 
the expression of Sirt1 and Pgc-1α was reduced during the light period, while during the dark 
period the expression was similar between groups. Fluctuating mRNA expression levels of the 
genes Rorc, Nfil3 and Dbp was similar between mouse groups.  
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Figure 2-2-10: Fluctuating mRNA expression patterns of Sirt1 and Pgc1-α are dampened in 
Rictor
aP2KO
 mice. Expression of target genes was determined in perivascular adipose tissue (PVAT) of 
control and Rictor
aP2KO
 mice at different zeitgeber times (ZT) over a period of 24 hours. Mice were 
kept under constant 12 hour light/ 12 hour dark cycles (lights on ZT 0: 7 am; lights off ZT 12; 7 pm). 
Prior experiment, mice were not starved. All values represent mean ± SEM, *P < 0.05, n=3 mice per 
group and time point. Gray shaded areas represent the 12 hour dark period. 
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3. Discussion 
3.1 Key players in vascular reactivity 
The occurrence of cardiovascular diseases including pathologies of the thoracic aorta is increasing 
due to prolonged life expectancy, obesity and associated comorbidities (e.g. hypertension and 
T2D) [228]. Traditionally, it was assumed that all physiological and pathophysiological changes of 
the blood vessel wall are mediated by bioactive molecules delivered by the blood stream through 
vascular endothelial cells (“inside-out” signaling). However, a growing body of evidence suggests 
that perivascular adipose tissue (PVAT) has beneficial effects on blood vessel function (“out-side-
in” signaling) in healthy conditions, which are impaired in various pathologies such as 
hypertension [229].  
To date, PVAT is widely accepted as an endocrine organ secreting vasoactive substances and 
affects the reactivity of the adjacent blood vessel [159]. Most studies analyzing PVAT properties 
and its contribution to vascular reactivity have widely focused on identifying molecules released 
from PVAT. Signaling pathways involved are less well understood.  
To understand the contribution of the mammalian target of rapamycin complex 2 (mTORC2) to 
PVAT function, I aimed to analyze gene expression in thoracic PVAT and blood pressure regulation 
in mice lacking Rictor mRNA expression in adipocytes and the brain. 
 
3.2 Perivascular adipose tissue  
3.2.1 Perivascular adipose tissue function and hypertension 
Anti-contractile properties of PVAT are mediated by vasoactive molecules. Their secretion was 
reported to be attenuated in hypertension [134]. Mechanisms contributing to changes in 
PVAT properties are however not well understood. In accordance with the function of PVAT, 
different mechanisms should be taken into consideration.  
In animal models of hypertension, an increase in cell density and reduced absolute PVAT 
mass were reported to be strongly associated with the loss of PVAT anti-contractile 
properties [163-165]. In Rictor
aP2KO
 mice, we observed a similar phenotype with increased 
cell density of the thoracic PVAT likely contributing to the attenuated vasoactive properties 
of PVAT. In addition to PVAT, cell density was increased in the interscapular brown adipose 
tissue (BAT), but not epididymal adipose tissue (EFAT) of Rictor
aP2KO
 mice (data not shown). 
Interestingly, these morphological changes resemble the phenotype of Rictor
MYf5cKO 
mice, lacking 
Rictor in brown adipocytes [230]. As PVAT has a phenotype similar to BAT [7], it would be of 
interest to assess PVAT vasoactive properties and vascular reactivity of the thoracic aorta in these 
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mice. However, at this point it remains unclear whether deletion of Rictor in adipocytes or the 
hypertensive phenotype causes the increase in perivascular cell density and warrants further 
investigation. 
Another reason for altered PVAT vasoactive properties is inflammation. In hypertension, PVAT 
gets inflamed [134, 138, 173, 231] which is associated with pathophysiological changes of the 
blood vessel wall [232]. Pro-inflammatory molecules can be secreted either directly from 
perivascular adipocytes or PVAT infiltrating immune cells. In Rictor
aP2KO
 mice, we previously 
reported that increased pro-inflammatory molecule expression in PVAT added to the changes in 
the vascular reactivity [223]. However, the percentage of infiltrating immune cells such as 
leukocytes did not change in these mice [223].  
In conclusion, in Rictor
aP2KO
 mice altered vasoactive properties of PVAT can be contributed to the 
increased perivascular cell density and the increased pro-inflammatory molecule expression 
without affecting immune cell content. It is feasible to assume that these alterations might affect 
PVAT properties under additional pathological inflammatory conditions. Further, a novel role of 
RICTOR/mTORC2 in inflammation is fostered by studies showing that the inflammatory response 
in mTORC2-deficient myeloid mouse cells and mouse embryonic fibroblasts as well as in dendritic 
cells with Rictor knock-down is only susceptible upon lipopolysaccharide (LPS) stimulation, but not 
under basal conditions [233, 234].  
3.2.2 Perivascular adipose tissue, mTORC2 and clock gene expression   
To connect physiological changes observed in Rictor
aP2KO
 mice to attenuated mTORC2 signaling, 
we analyzed the expressed genome in PVAT of Rictor
aP2KO
 mice and controls. Gene expression 
analysis uncovered a significant contribution of RICTOR/mTORC2 to peripheral core clock gene 
expression. Core clock genes form the molecular basis of the circadian clock [51] and 
misalignments were reported to enhance metabolic dysfunction and inflammation [80, 235]. An 
extended analysis of mRNA expression levels over a 24 hour cycle identified the core clock genes 
Rora, Cry1, Per1, Per2 and Clock to be changed in PVAT of Rictor
aP2KO
 mice. Interestingly, 
inflammatory capability of these genes was shown for the adipose tissue [236, 237] and the 
cardiovascular system [238] providing evidence that misalignment of the circadian clock in these 
tissues contributes significantly to inflammatory processes.  
Staggerer mice (Rorα
sg/sg
), with loss-of-function of the Rorα gene, displayed elevated susceptibility 
to the development of atherosclerosis in the blood vessel wall upon high-fat diet feeding [239]. 
These results are in line with findings that pro-inflammatory molecule expression (e.g. Tnfα, Il-1α) 
[240] and LPS stimulated inflammatory response [241] were increased in these mice. The anti-
inflammatory capability of RORα is probably mediated by the transcriptional induction of the NF-
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κB (nuclear factor of kappa light polypeptide gene enhancer in B cells) negative regulator Iκ-Bα 
(nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) [242]. 
Controversially, pro-inflammatory capability of RORα was reported as Rorα
sg/sg
 mice were 
protected against diet-induced obesity and white adipose tissue (WAT) inflammation [192, 193]. 
Thus, data imply that RORα has anti- and pro-inflammatory capability, which might depend on the 
tissue analyzed and manifests in variable phenotypes.  
In a nutshell, the changed peripheral core clock gene expression might explain the pro-
inflammatory state of PVAT, which we previously reported in Rictor
aP2KO
 mice [223] and thus 
contribute to changes in the vascular reactivity. Given the fact that components of the molecular 
clock are involved in anti- and pro-inflammatory processes, a profound understanding of how the 
circadian clock and inflammatory processes are interconnected with each other might open new 
directions in the development of treatment options for common cardiovascular diseases such as 
hypertension. 
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3.3 Blood pressure regulation in Rictor
aP2KO
 mice 
The present study uncovers an unknown contribution of RICTOR/mTORC2 to blood pressure 
regulation in mice. In Rictor
aP2KO
 mice, the mean (MAP) and the diastolic (DAP) arterial pressure as 
well as the heart rate (HR) were slightly elevated and resembled a pre-hypertensive phenotype in 
human subjects [243]. In addition, locomotor activity, specifically the time mice spent active, was 
increased. In general, different mechanisms on the whole body level contribute to the regulation 
of blood pressure. Thus, it is likely that, in addition to the functional and structural changes of 
PVAT, other mechanisms contribute to the elevation in blood pressure of Rictor
aP2KO
 mice as 
discussed in the following: 
 
3.3.1 Hyperinsulinemia 
In addition to the already reported hyperinsulinemic and slightly insulin resistant state [215, 244], 
we found insulin plasma levels to be increased in Rictor
aP2KO
 mice at specific time points over a 24 
hour cycle.  
In healthy subjects, insulin exerts protective effects on the vasculature. Postprandial, acute 
hyperinsulinemia increases NO and prostaglandins availability to vascular smooth muscle cells 
(VSMC). This promotes vasodilation [47] and small physiological changes in blood pressure [245]. 
In contrast, chronic hyperinsulinemia which compensates insulin resistance [246], can facilitate 
changes in the insulin signaling in the vasculature. This enhances the secretion of vasoconstrictors 
such as endothelin-1 [247]. As a consequence, the progression of vascular dysfunction and 
hypertension might be promoted [47].  
Further evidence of the noticeable contribution of insulin, while not per se, to the development of 
hypertension is provided by studies in humans and animals. In type 2 diabetes mellitus (T2D) 
patients, hypertension is twice as common as in healthy subjects [248]. Genetically hypertensive 
rats display elevated insulin levels [249, 250], suggesting a common genetic predisposition of 
hyperinsulinemia and hypertension. However, a relationship between hypertension and 
hyperinsulinemia/insulin resistance is not always obvious. Not all T2D patients are hypertensive, 
and hypertensive patients are not necessarily hyperinsulinemic and/or insulin resistant [251-253]. 
This hypothesis is further strengthened by a missing association of hyperinsulinemia and 
secondary hypertension [254]. Thus, the cumulative relationship of hypertension, 
hyperinsulinemia and insulin resistance might have different reasons: (1) hyperinsulinemia and 
insulin resistance can be secondary to other pathophysiological changes observed in hypertensive 
subjects, or (2) hypertension, insulin resistance and hyperinsulinemia may arise from different 
unrelated processes.  
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Hyperinsulinemia can contribute by several mechanisms to the progression of vascular 
dysfunction and hypertension. These processes include elevated sympathetic nervous system 
(SNS) activity, structural and functional changes of the kidney, and a dysfunctional RAA system 
[255]. Long-term pathophysiological changes of these mechanisms can increase vascular 
resistance, cardiac output, and fluid retention in the kidney [256-258] causing elevated blood 
pressure. To what extend these parameters contribute to the changes in blood pressure of 
Rictor
aP2KO
 mice requires further investigations. 
 
3.3.2 Natriuretic peptides  
Chronic blood pressure elevations are associated with compensatory morphological changes of 
the heart and altered cardiac natriuretic peptide (NP) expression [32]. The NP family includes the 
mature proteins atrial NP (ANP) and B-type NP (BNP), which are predominantly secreted from 
cardiomyocytes, and C-type NP (CNP), found in the CNS and endothelium. NPs are hormonal 
regulators of vasodilation and natriuresis as well as inhibitors of the SNS and their role in blood 
pressure regulation is well established [259]. Transgenic mice overexpressing a non-functional 
ANP display a hypertensive phenotype [260]. In pre-hypertensive Rictor
aP2KO
 mice, cardiac Anp and 
Bnp mRNA expression levels were reduced. These findings are in line with human studies showing 
that a pre-hypertensive state is characterized by a deficiency of circulating ANP and BNP levels 
[261, 262]. A genetically predisposition in humans reduces circulating levels of ANP and BNP, 
which increases the risk of hypertension [261, 263]. Moreover, with low circulating levels, the 
ability of NPs to effectively inhibit SNS and RAAS activity gets lost [264]. Taken together, previous 
studies support a possible contribution of the reduced cardiac Anp and Bnp mRNA expression to 
the blood pressure elevations in Rictor
aP2KO
 mice.  
Interestingly, NPs were reported to stimulate lipolysis in adipocytes during exercise [265]  and 
reduced plasma levels of NPs were identified as a common predisposition for metabolic and 
cardiovascular disorders [32, 266]. A common initiating factor might be insulin as concentrations 
of circulating NPs are inversely related to plasma insulin levels [267-270]. This assumption is 
strengthened as transgenic mice overexpressing Bnp were resistant to diet-induced obesity [271]. 
Moreover, a “natriuretic handicap” characterized by low circulating ANP and BNP levels is 
common to obese subjects [269, 272]. Interestingly, in patients with T2D the release of ANP from 
the heart was impaired and the ability of ANP to lower blood pressure reduced [273].  
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3.3.3 Contribution of locomotor activity to elevation in blood pressure  
Activity and rest exert profound influences on the physiology of small rodents [274] and are 
important parameters affecting blood pressure in mice.  
In Rictor
aP2KO
 mice, we demonstrated an overall increase in locomotor activity parameters and its 
physiological decrease during the dark period was strongly reduced. The intensity of activity 
followed a similar fluctuating pattern as established for MAP and HR during the dark period. Thus, 
the increased locomotor activity observed in Rictor
aP2KO
 could be one important parameter 
responsible for the elevations in blood pressure and HR as well as the strong impairment of their 
physiological decline during the dark period. A similar observation has been made by Kim et al. 
showing that differences in MAP between mouse groups are no longer evident if analyzing MAP 
only in intervals with no activity [275]. A possible contribution of locomotor activity to blood 
pressure readings has further been provided by Sheward et al. demonstrating that episodes of 
activity and rest mainly account for changes in MAP and HR in vasointestinal peptide receptor 2 
knockout mice [274]. These findings might further explain why the infusion of the specific iNOS 
inhibitor 1400W, did not result in lower blood pressure in Rictor
aP2KO
 mice. 
 
3.3.4 Conclusion 
To the best of our knowledge, this is the first study showing that RICTOR/mTORC2 contributes to 
the regulation of blood pressure and its fluctuating patterns in mice over a 24 hour light/dark 
cycle. Based on the findings of the present study and current literature, it is likely that several 
mechanisms contribute to the observed changes in blood pressure regulation in Rictor
aP2KO
 mice.  
In my opinion, the present study and available literature suggest that the elevated locomotor 
activity is mainly responsible for the increase in blood pressure of Rictor
aP2KO
 mice, especially 
during the 12 hour dark period. This assumption is based on the finding that the patterns of MAP 
and HR are highly similar to those of the intensity of activity (see 2.1.9/ Figure S2) in these mice. 
Confirming data from other rodent studies, findings presented here underscore the importance of 
considering locomotor activity if analyzing blood pressure data in free-moving mice. To clarify the 
contribution of elevated locomotor activity to the blood pressure increase in Rictor
aP2KO
 mice, 
blood pressure should be recorded in immobilized Rictor
aP2KO
 and control mice using tail cuff 
method. Measurements might allow estimating the effective impact of the locomotor activity on 
blood pressure and to what extend other parameters might account for blood pressure elevations 
in Rictor
aP2KO 
mice. However, with the telemetric system used in this study, only horizontal 
movements of mice across the cage, but not specific behavioral parameters could be analyzed.  
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Other factors such as the hyperinsulinemic state and/or the altered NP system might contribute 
additionally to the blood pressure and locomotor activity elevations. However, precise 
mechanisms have yet to be identified. Possible explanations might be: 
(1) Changes in blood pressure and locomotor activity might be secondary to the 
hyperinsulinemia in Rictor
aP2KO
 mice. This hypothesis is strengthened by studies in 
humans and dogs showing that hyperinsulinemia is associated with an increase in SNS 
activity [276] and heart rate [277]. Daily variations in MAP, HR and locomotor activity are 
mediated by the CNS [33, 278]. Functional changes in the CNS, particularly within regions 
controlling blood pressure and locomotor activity, might impact the daily regulation of 
these parameters. Thus, in Rictor
aP2KO
 mice the observed changes in blood pressure and 
locomotor activity might reflect an autonomic imbalance, which is initially triggered by 
increased insulin levels.  
(2) The reduced Anp and Bnp expression in the heart might contribute to the increase in 
blood pressure in Rictor
aP2KO
 mice. Both peptides are released from the heart into the 
blood stream upon mechanical strain of the atria [259]. Interestingly, action of ANP was 
reported in the hypothalamus to influence cardiovascular homeostasis, blood pressure, 
and SNS activity [259]. Therefore, the deregulated NPs system might be an important 
contributor to cardiovascular changes of Rictor
aP2KO
 mice. However, additional studies are 
required to evaluate possible mechanisms by which aP2 promoter-driven deletion of 
Rictor causes the alterations in the NP system. 
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3.4 Role of RICTOR/mTORC2 in clock gene expression in the suprachiasmatic nucleus 
Rictor mRNA expression in the brain (SCN and cortex) and absolute brain mass are reduced in 
Rictor
aP2KO
 mice. These findings are in line with data published by Thomanetz et al. demonstrating 
that mTORC2 is of particular importance for brain functions [213]. Both, blood pressure and 
locomotor activity are also regulated through different neural mechanisms. Thus, an effect of the 
deletion of Rictor in the brain has to be considered likely facilitating blood pressure and 
locomotor activity changes. A key role in the regulation of daily blood pressure and locomotor 
activity fluctuations is achieved and coordinated by the biological master clock, the 
suprachiasmatic nucleus (SCN) located in the anterior hypothalamus. SCN lesions in rats [93, 94] 
and mutations of core clock genes in the SCN impaired the daily regulation of blood pressure and 
promoted the progression of hypertension [279, 280]. Consequently, it was important to analyze 
clock gene expression in the SCN of Rictor
aP2KO
 mice. Despite reduced Rictor expression, core clock 
gene expression patterns over a 24 hour period were not changed in Rictor
aP2KO
 mice compared to 
controls. Thus, data imply that physiological changes of the blood pressure and locomotor activity 
are likely due to alterations downstream or independent of the molecular clock mechanism in the 
SCN. However, in Rictor
aP2KO
 mice deletion of Rictor in the brain was not restricted to the SCN and 
mice exhibited reduced absolute brain mass. Accordingly, a possible impact of the Rictor deletion 
in other brain regions on the observed phenotype has to be considered. It would be of particular 
interest to study sympathetic and parasympathetic output of the medullary cardiovascular center, 
the core of blood pressure regulation driving vasculature, heart and kidney functions to regulate 
long-term blood pressure [1].  
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3.5 Gene expression profiling in perivascular adipose tissue of Rictor
aP2KO
 mice 
Large scale gene expression profiling between different biological groups can be performed using 
micro arrays [281]. This technique is a powerful tool to discover new biological targets. However, 
sensitivity and specificity of micro arrays, variability of platforms and biological samples used are 
major limitations of this technique [282]. Therefore, it is required to critically validate the 
expression data to estimate their quality using an independent method. Usually, the method of 
choice is quantitative RT-PCR (qRT-PCR).  
In the present study, the micro array data analysis identified 68 differentially expressed genes in 
PVAT of Rictor
aP2KO
 mice compared with controls. For the validation of micro array data, the 20 
top-ranked genes (10 most increased and 10 most reduced genes) were chosen. Seven genes 
were validated by qRT-PCR and found to be differentially expressed in PVAT of Rictor
aP2KO
 mice. 
Validation results are in line with the statistical analysis of the micro array data, which predicted a 
false discovery rate (FDR) of ~ 30 % of all differentially expressed genes. The high correlation 
further suggests that all the different steps necessary to perform a micro array and a qRT-PCR 
were done accurate. 
Validation of target genes showed that Irf4, Npas2, Mcpt-4, Sesn2 and Spry4 were significantly 
increased in PVAT of Rictor
aP2KO
 mice. Serpine1 and S100b showed a reduction in their expression 
levels. Interestingly, the fold changes detected by qRT-PCR were mostly similar to those extracted 
from the micro array. Differential expression of the target genes Trdn, Cry1, and Nfil3 in PVAT 
could not be confirmed using qRT-PCR. Possible reasons might be the heterogeneity of individual 
samples, small expression values, rather small differences between groups and/or the FDR of 
approx. 30 %. Interestingly, mRNA expression levels of the target genes Rev-Erbβ and Chac1 were 
not detected in PVAT of Rictor
aP2KO
 and control mice. Possible explanations might be that either 
the genes were indeed not expressed in PVAT or non-binding primer pairs were used for the qRT-
PCR.  
Irf4 showed the highest increase in gene expression in PVAT of Rictor
aP2KO
 mice. As a member of 
the interferon-regulatory factor (IRF) family, IRF4 is involved in a wide range of immune functions, 
including lymphopoiesis, macrophage differentiation and the regulation of innate immunity, 
particularly as effectors of toll-like receptor (TLR) signaling [283, 284]. Irf4 expression is restricted 
to immune cells and adipocytes. In adipocytes, Irf4 expression depends on the availability of 
nutrients and is modulated via the insulin-FOXO1 signaling pathway [285]. A role of IRF4 has been 
shown during adipogenesis [286] and in mature adipocytes by the transcriptional induction of the 
adipocyte triglyceride lipase (Atgl) and the hormone-sensitive lipase (Hsl). [285]. However, steady 
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state mRNA expression levels of genes associated with the lipid metabolism and cholesterol 
synthesis did not change in PVAT of Rictor
aP2KO
 mice (see 2.2.2, figure 2-2-6).  
In addition, IRF4 was associated with the regulation of the thermogenesis and mitochondrial 
biogenesis in brown adipocytes [287]. Interestingly, cardiac ANP and BNP were reported to induce 
thermogenesis in BAT [288]. Mice exposed to cold stimuli showed increased circulating NP levels. 
Expression of the NP receptors A and B was elevated, while the expression of the clearance 
receptor NPRC was significantly reduced. Taken together, data of the present study and current 
literature might suggest a putative impact of the increased Irf4 expression on the lipid metabolism 
and thermogenic processes in PVAT of Rictor
aP2KO
 mice. This might involve changes in the NP 
system. How IRF4 and NPs are associated with each other and a possible common contribution to 
changes in PVAT functions needs to be shown. As genes possessing lipolytic activity (e.g. Fdps, 
Nsdhl) are also regulated post-transcriptionally on the protein level, an analysis of the abundancy 
of these proteins and e.g. their phosphorylation state might shed light on the impact of the 
increased Irf4 expression in PVAT. In addition, an analysis of Irf4 expression and the lipid 
metabolism in an adipose tissue more relevant for the rapid energy turnover would provide 
interesting results. 
In contrast to Irf4, Serpine1 showed the highest reduction in gene expression in PVAT of 
Rictor
aP2KO
 mice. SERPINE1 is a serine protease inhibitor of the tissue (tPA) and urokinase 
plasminogen activator (uPA), and involved in atherosclerotic and thrombotic plaque formation 
[289]. The transcription of Serpine1 is mainly regulated by the transforming growth factor beta-1 
(TGF-ß1) [290] and ECs are the major source of circulating SERPINE1. However, its expression was 
also reported in adipose tissue [291]. In vitro, inhibition of SERPINE1 using its specific inhibitor 
PAI-039 reduced the adipogenesis of human preadipocytes and led to the formation of atypical 
mature adipocytes [292]. Interestingly, in obese humans, circulating SERPINE1 levels positively 
correlated with the body mass index (BMI) [293, 294] and circulating SERPINE1 levels were 
reported to be elevated in ob/ob mice [295]. The application of PAI-039 reduced SERPINE1 levels 
in blood, EFAT mass and overall body weight in mice fed HFD [292]. In T2D patients an association 
of circulating SERPINE1 levels and the onset of diabetes was suggested [296]. Thus, data might 
implicate a putative impact of the reduced Serpine1 expression on PVAT functions and 
morphology as well as an association with the hyperinsulinemic state in Rictor
aP2KO
 mice. 
Mcpt-4 mRNA expression was increased in PVAT of Rictor
aP2KO
 mice. The MCPT-4 chymase belongs 
to a family of serine proteases. Similar to other family members, MCPT-4 is primarily expressed in 
mast cells and released upon inflammatory response and host defense [297]. In addition, MCPT-4 
was shown to play a key role in the generation of the vasoactive peptides ANGII and endothelin-1 
Discussion 
86 
 
[298, 299]. Deregulation of MCPT-4 signaling pathways was suggested to contribute to the 
pathogenesis of hypertension and atherosclerosis [297]. Taken together, the increase in Mcpt-4 
expression in PVAT of Rictor
aP2KO
 mice might contribute to the altered vascular reactivity and 
blood pressure elevations in these mice. In this context, the formation of the ANG II in PVAT 
and/or aortic tissue might be involved and needs further investigations. 
Sesn2, found to be increased in Rictor
aP2KO
 mice, encodes a member of the sestrin family and is 
induced by the p53 tumor suppressor protein. SESN2 is known to activate AMP-activated protein 
kinase (AMPK) and suppresses mTORC1-S6K activity [300, 301]. SESN2 was proposed to function 
mainly in the regulation of cell growth and survival in response to DNA damage and oxidative 
stress [302]. Lee et al. demonstrated that hypernutrition up-regulates SESN2 expression to 
maintain metabolic homeostasis in liver of obese mice [303]. Conversely, deletion of Sesn2 in liver 
impaired AMPK and mTORC1-S6K and promoted glucose intolerance and insulin resistance [303]. 
Furthermore, double knockout of Sesn2 and Sestrin 3 in liver impaired hepatic mTORC1-S6K 
activation and promoted insulin resistance even in the absence of a nutritional overload [303]. 
Thus, these studies indicate that SESN2 plays a key role in the liver to control the lipid and glucose 
metabolism. Whether this translates to the adipose tissue metabolism and the impact of the 
increased Sesn2 expression on PVAT function in Rictor
aP2KO
 mice remains to be shown. 
To the best of my knowledge, the information about S100b/S100B expression in adipose tissue or 
its association with the mTORC2 signaling network is limited. In Rictor
aP2KO
 mice, S100b mRNA 
expression levels were reduced in PVAT. S100B is a low molecular weight protein characterized by 
two calcium binding sites and exists as a homodimer [304, 305]. S100B is primarily expressed in 
the CNS [306] and is associated with neurodegenerative diseases [307]. Interestingly, in humans 
S100B levels were elevated upon inflammatory response in the CNS and duodenal mucosa of the 
intestine, which stimulated iNOS synthesis and NO production in these tissues [308, 309]. Only 
recently, circulating S100B levels were discovered to positively correlate with blood pressure 
levels and found to be elevated in pre- and hypertensive patients [310]. Furthermore, circulating 
S100B levels were identified to correlate with the BMI in humans and might reflect adipose tissue 
mass [311]. Taken together, reduced S100b expression in PVAT might contribute to the impaired 
vascular reactivity of Rictor
aP2KO
 mice. However, a possible association of S100B to the increased 
iNOS expression in PVAT in these mice should be critically evaluated. In contrast to the 
inflammatory response in the CNS, in the present study S100b expression was reduced in 
inflamed PVAT of Rictor
aP2KO
 mice. Furthermore, stimulation of astrocytes with TNF-α did not 
potentiate NO production in a S100B-dependent manner [308]. Thus, the effect of S100B might 
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be tissue-specific and/or depend on acute and chronic stimuli. In regard to the pre-hypertensive 
phenotype in Rictor
aP2KO
 mice, it would be of interest to measure circulating S100B concentration. 
In summary, using the micro array technology we discovered that the aP2-promoter/ CRE 
recombinase-driven deletion of Rictor leads to (1) at least seven differentially expressed genes 
and (2) the identification of the circadian rhythm as the most regulated pathway in PVAT. 
Literature might suggest a putative role for these genes to the functional and morphological 
changes in PVAT of Rictor
aP2KO
 mice. Whether and to what extend these genes interact with each 
other is not yet known. In order to examine whether the differential expression of the seven 
genes translates on changes in the protein level, a Western blot analysis should be performed. 
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3.6 Fluctuating expression of Rictor and mTORC2 downstream targets in adipose tissue 
In addition to the master clock located in the SCN, peripheral clocks in various tissues including 
liver, pancreas, heart and adipose tissue have been identified [85]. Peripheral clocks dominate 
tissue-specific metabolism with a similar molecular clock mechanism as in the SCN. While the SCN 
is mainly entrained to light cues, peripheral clocks can be entrained to SCN-derived signals, 
feeding and temperature cues [235]. Tight daytime-dependent regulations of gene expression 
were found in many tissues and are necessary for a coordinated tissue-specific metabolic output. 
Similar, the circadian clock regulates adipose tissue metabolism [312]. This affects triglyceride 
storage, free fatty acid release, adipokine and cytokine secretion [190] and further manifests in 24 
hour fluctuating concentrations of circulating adipokines [120, 313]. Moreover, fasting and 
feeding periods are important environmental cues to achieve a balanced adipose tissue 
metabolism and that the availability of nutrients and other metabolites contributes significantly to 
the generation of cellular rhythmicity [225-227].  
The integration of fasting/feeding periods might involve mTOR complexes as both complexes are 
responsive to nutrient- and growth factor-derived signals [194, 208]. In liver, mTORC1 activity is 
regulated by the circadian clock [314, 315] and time of feeding affects mTORC1 signaling activity 
[316, 317]. Although clear evidence whether the mTORC2 signaling activity is regulated in a 
circadian fashion is still lacking, Zhang et al. showed that in hepatocytes BMAL1 maintained the 
protein stability of RICTOR, but not Rictor mRNA expression [318].  
In adipose tissue, data of the present study demonstrate that Rictor/RICTOR expression in PVAT, 
BAT and EFAT dependents on the time of the day. Fluctuating Rictor/RICTOR expression might 
further translate to the mTORC2 signaling activity. In EFAT and PVAT the phosphorylation of the 
mTORC2 signaling target AKT at serine 473 (pAKT
Ser473
) was higher at the beginning of the resting 
(light) period of mice. Major gaps in the understanding include how fluctuating Rictor/RICTOR 
expression and mTORC2 activity are regulated in adipose tissue. The control of Rictor/RICTOR 
expression might involve BMAL1 similar to hepatocytes [318] or can be completely independent 
of the circadian clock. Further, Khapre et al. demonstrated that mTor gene expression is 
negatively regulated by BMAL1 impairing mTORC1 signaling activity in a daytime-dependent 
manner [314]. This might also apply to the mTORC2 kinase activity, as mTOR is common to both 
complexes. However, the non-mTORC2 target side pAKT
Thr308
 showed a similar phosphorylation 
pattern as observed for pAKT
Ser473
,
 
at least in EFAT. Thus, to what extend a possible fluctuating 
mTORC2 kinase activity is responsible for the daytime-dependent phosphorylation of pAKT
Ser473 
needs further investigation. To obtain detailed insight on how nutrient and growth factor 
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availability is integrated on the cellular level to influence adipose tissue metabolism and involves 
mTORC2 requires further investigation. 
Interestingly, patterns of fluctuating mRNA expression levels of the nutrient sensors SIRT1 
(Sirtuin1) and PGC-1α (Pparg co-activator 1α) were similar to Rictor and impaired in Rictor
aP2KO
 
mice. As the expression and activity of SIRT1 is regulated by the circadian clock [319, 320] findings 
might provide a link between the mTORC2 signaling network and molecular components of the 
circadian clock in adipose tissue. How deletion of Rictor in adipocytes and the brain cause the 
reduction in Sirt1 and Pgc-1α mRNA expression levels has yet to be shown. As SIRT1 directly links 
the metabolic state with transcriptional gene regulation, SIRT1 enzymatic activity and the 
transcriptional regulation of SIRT1 target genes should be analyzed to obtain new insights into 
SIRT1 function in adipose tissues of Rictor
aP2KO
 mice. 
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3.7 Limitation of the study 
 
3.7.1 Targeted deletion of Rictor in adipocytes using CRE/loxP system 
A powerful tool to design genetically modified mouse strains is the CRE site-specific DNA 
recombinase of the bacteriophage P1 [321]. The CRE recombinase recognizes a 34 bp DNA 
fragment (loxP; locus of X-over of P1) within the bacteriophage genome and mediates DNA 
recombination between two loxP sites [321]. This technique was adapted to manipulate the 
mouse genome to understand the function of specific genes in cell and tissue metabolism. 
However, global deletion of the gene of interest was often limited due to embryonic lethality and 
missing tissue-specificity. Therefore, knockout mouse models expressing the CRE recombinase 
under the control of tissue-specific gene promoters were generated. To knockout specific genes in 
adipocytes, the aP2 gene promoter was widely used. However, over the last years aP2 was 
recognized to be expressed in other tissues and cell types. Moreover, expression of the Cre/CRE 
recombinase in non-adipose tissues/cells was reported in several knockout mouse models using 
the aP2/CRE/loxP technology [322]. In the present study, we took advantage of the aP2/CRE/loxP 
technology to generate a mouse model lacking Rictor (Rictor
aP2KO
) in adipocytes. In addition to 
adipocytes, the Cre recombinase was expressed in other tissues (e.g. the brain) and Rictor mRNA 
expression levels were reduced in the brain of these mice. These findings raise the question, how 
specific phenotypical changes observed in Rictor
aP2KO
 mice can be assigned to targeted gene 
deletion in adipocytes. As the brain is a central regulator of various physiological processes 
including blood pressure and adipose tissue metabolism, results obtained should be critically 
scrutinized. 
To overcome the disadvantages of the aP2/CRE/loxP approach, there have been different efforts 
to ensure CRE recombinase expression to be more stringent adipocyte-specific. One possible 
alternative approach might be the adiponectin (Adipoq) gene promoter [323] as expression of the 
transgenic Cre is more restricted to mature adipocytes [323]. Taking advantage of the myogenic 
factor 5 (Myf5) gene promoter would further allow to specifically knockout the gene of interest in 
brown adipocytes as Myf5 is not expressed in white mature adipocytes [230]. As PVAT 
characteristics are similar to the phenotype observed in BAT, it would be of interest to 
characterize tissue-specific Rictor
Myf5
 knockout mice and how possible phenotypical changes of 
the Rictor
Myf5
 mice correspond to the Rictor
aP2KO
 mice phenotype.  
 
3.7.2 Cre-recombinase expression in adipocytes of Rictor
aP2KO
 mice 
In addition to the tissue-specificity of the aP2 gene promoter, other limitations of conditional 
gene targeting involving CRE/loxP evolved and might explain underlying mechanisms for the 
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observed reduction of only 50 - 75 % in Rictor gene expression in the mice used in the present 
study.  
(1) It has been reported that the integration side of the Cre recombinase transgene in the 
mouse genome strongly influences the expression of the Cre recombinase [324, 325]. This 
might result in mosaic expression pattern of the Cre recombinase within a given tissue 
and thus varying levels of CRE-mediated loxP recombination. 
(2) Genetically modified mice are mostly generated through random integration of the Cre 
recombinase transgene into the mouse genome [321]. As a result, unspecified genetic 
interactions (e.g. transactivation, silencing effects) may occur at the DNA integration side 
possibly affecting the efficiency and specificity of the CRE recombinase within given 
tissues.  
(3) The breeding strategy used to maintain the mouse colony has to be considered. In the 
current experimental approach, we mated control mice
 
(Rictor
fl/fl
)
 
not expressing the Cre 
recombinase transgene (Cre
-/-
) with Rictor knockout mice (Rictor
aP2KO
) expressing one Cre 
allele (Cre
-/+
). Compared with other breeding strategies involving Cre
+/+
 genotypes, this 
might result in lower CRE recombinase expression decreasing recombination events. 
However, maintaining Cre
+/+
 genotypes fails to produce control littermates and needs an 
additional colony of control mice.  
(4) Maintenance of the mouse colony for several generations might cause changes in the 
Cre/CRE recombinase expression and/or efficacy. As a result of chromatin inactivation or 
multiple recombination events expression of the Cre recombinase might by reduced or 
completely abolished. 
However, a 50 - 75 % reduction of Rictor gene expression is in a range as observed for other 
transgenic mouse strains using the CRE/loxP system [326]. For example, CD19-Cre mice display 
recombination of 55 - 95 % [327]. Nevertheless, based on the expression data obtained from 
different tissues, even a 50 - 75 % reduction in Rictor mRNA expression strongly affected the 
phenotype in Rictor
aP2KO
 mice. 
 
3.7.3 Locomotor activity recordings in Rictor
aP2KO
 mice 
Telemetric measurements revealed elevated locomotor activity in Rictor
aP2KO 
mice. However, 
specific behavioral parameters as putative causal factors for the elevated locomotor activity 
couldn’t be analyzed using the telemetric system and require further experiments. One behavioral 
parameter might be food intake as contributing significantly to fluctuating patterns of locomotor 
activity over a 24 hour light/dark cycle [328]. Thus, observed elevations in locomotor activity and 
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the reduced decline during the 12 hour dark period might reflect changes in food intake, which 
was not investigated in the study presented here. Additional experiments investigating e.g. food 
intake over a 24 hour light/dark cycle, might ascertain the reason of the increase in locomotor 
activity in Rictor
aP2KO 
mice in more detail.   
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3.8 Future directions  
One of the most interesting follow-up questions of the present study is which proportion of the 
phenotypical changes observed in Rictor
aP2KO
 mice can be attributed to Rictor deletion in (1) 
adipose tissues and/or (2) in the brain. Taking advantage of gene promoters allowing a more 
restricted expression of the CRE recombinase to adipose tissue (e.g. Myf5 and Adipoq) or brain 
(e.g. Nexin) and to understand the contribution of RICTOR/mTORC2 in these tissues in regard to 
changes in vascular reactivity and blood pressure regulation in Rictor
aP2KO
 mice. 
 
The mRNA expression of NPs and NP receptors was altered in the heart and adipose tissue of 
Rictor
aP2KO
 mice. The involvement of NPs in blood pressure regulation is well established. 
Moreover, evidence of an NPs association with lifestyle-related metabolic disorders (e.g. T2D and 
obesity) has been accumulated. Thus, the investigation of the following issues could contribute to 
a better understanding of how the deletion of Rictor add to the changes in the NP system and its 
signaling pathways, and the dysregulation of the NPs system to blood pressure elevations in 
Rictor
aP2KO
 mice:  
(1) How does deletion of Rictor in adipocytes and/or the brain contribute to the reduced NP 
and NP receptor expression in the heart of Rictor
aP2KO
 mice? Are there other putative 
factors than the slight increase in blood pressure? 
(2) Does the reduced Anp expression in the heart translate to the protein level and possible 
cause a reduction of ANP plasma levels in Rictor
aP2KO
 mice? 
(3) ANP increases physiological renal sodium secretion and counteracts the RAA system to 
cause vasodilation. Although there are no morphological indications of renal dysfunction 
(e.g. fibrosis) in Rictor
aP2KO
 mice, it would be of interest to analyze whether the reduced 
cardiac Anp expression causes pathophysiological changes in the RAA system. 
(4) What putative changes cause the reduction of the Anp and Nprc expression in EFAT 
adipocytes and PVAT? The deletion of Rictor, the hyperinsulinemic state and/or other yet 
to be identified factors? 
Beside its impact on clock genes, the expression of other genes is altered by the deletion of Rictor 
in PVAT. mRNA expression of Irf4, Npas2, Mcpt-4, Sesn2, Spry4, Serpine1 and S100b were 
significantly changed in PVAT of Rictor
aP2KO
 mice. It warrants further investigation to clarify a 
putative role of these genes in the pathophysiological changes of PVAT properties and vascular 
reactivity in these mice, and overall in the mTORC2 signaling network. 
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It would be of interest to elucidate whether Rictor mRNA expression in adipose tissue is 
modulated by molecular components of the circadian clock or follows a diurnal expression 
pattern. To this end, in a first step 24 hour mRNA expression patterns of Rictor in adipose tissues 
have to be analyzed in Rictor
aP2KO
 mice kept under constant conditions (e.g. complete darkness). 
Persistence of the fluctuating 24 hour mRNA expression patterns would allow assigning Rictor 
gene expression in adipose tissue as circadian. In a second step, studies to delineate 
mechanistically the impact of the molecular components of the circadian clock on Rictor 
expression are needed. 
  
Discussion 
95 
 
3.9 Conclusion 
In the present dissertation, RICTOR/mTORC2 in the brain and adipose tissue was identified as a 
novel regulator of fluctuating physiological processes such as blood pressure and locomotor 
activity. This might involve the hormones natriuretic peptide and insulin, while the SCN does not 
seem to contribute to the pathophysiological changes of these processes in Rictor
aP2KO
 mice. A 
genome wide expression analysis in PVAT identified the clock genes, forming the molecular basis 
of the peripheral circadian clock, to be changed in Rictor
aP2KO
 mice. Changed clock gene expression 
might contribute to the inflamed PVAT as well as altered vascular reactivity of these mice. In 
addition, evidence was provided for a fluctuating mTORC2 activity in PVAT and EFAT, and a 
possible association with the peripheral clock and nutrient sensors in PVAT. Future studies to 
elucidate these complex interactions in the adipocyte-brain axis are necessary. This may 
contribute to a better understanding of how fluctuating physiological processes are regulated by 
these tissues. Our findings might lead to the identification of novel drug targets and the 
development of effective treatments against hypertension and dysfunctional adipose tissue 
metabolism. 
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Appendix 
ADDITIONAL METHODS 
Recording of blood pressure and locomotor activity in mice using radiofrequency transmitters - 
hardware set-up  
Rictor
aP2KO
 mice and control littermates (n=5/6) were implanted with a radiofrequency transmitter 
(TA11PA-C10, Data Sciences International, St. Paul, MN, USA) via the left carotid artery. 
Radiofrequency transmitter used allowed recording of mean, diastolic and systolic arterial 
pressure, pulse pressure, heart rate, respiratory rate and locomotor activity. Each transmitter had 
a weight of 4 g. Hardware set-up is shown in figure A-1. 
Cages with one mouse each were positioned above a receiver plate (RPC-1, Data Sciences 
International, St. Paul, USA). Receiver plates were connected with a data exchange matrix 
transmitting telemetric data. Data were collected using Dataquest A.R.T. system 4.2 (Data 
Sciences International, St. Paul, USA).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-1: Hardware set-up of blood pressure and locomotor activity recordings in Rictor
aP2KO
 
mice and control littermates. Figure adapted from www.datasci.com 
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Recording of blood pressure and locomotor activity in mice using radiofrequency transmitters - 
timeline post-operative animal care  
Mice were implanted with the radiofrequency transmitter (TA11PA-C10) at day 0. In addition to 
the standard chow in the food box, mice were provided with some standard chow directly inside 
the cage. Days zero to four after surgery, mice were single-caged at 30 °C. Temperature of the 
warming-cabinet was reduced to 25 °C at day five after surgery. Telemetric measurements were 
started at day eight after surgery. 
 
  
 
 
 
 
 
 
 
 
 
Figure A-2: Normalization of the mean arterial pressure and the heart rate after transmitter 
implantation. Radiofrequency transmitters (TA11PA-C10) were implanted via the left carotid artery 
at day zero. During the post-operative period, mice were kept at 29°C (days zero to four) and 25°C 
(days five to seven). For final data analysis, only telemetric data obtained from day eight on were 
considered. MAP (mean arterial pressure), HR (heart rate) 
 
Implantation of osmotic mini pumps in Rictor
aP2KO
 mice and control littermates 
For application of the iNOS-specific inhibitor 1400W (10mg/kg/day) or saline as solvent control, 
Alzet™ mini pumps (model 2001; DURECT Corporation, CA, USA) filled with either sterile 1400W 
or saline were implanted subcutaneously 14 days post telemetry sender implantation in 
Rictor
aP2KO
 mice. Surgery was performed under isoflurane anesthesia. Average filling volume was 
220 μl and pumping rate 1μl/hour. 
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mRNA expressional analysis of the Cre-recombinase  
Tissue dissection, RNA isolation, reverse transcription of RNA and qRT-PCR were performed as 
outlined in 2.1.10. The Cre-recombinase primer pair was designed alongside housekeeping genes. 
The sequences of the Cre-recombinase primers were as follows: 
Forward primer: 5'-CGT ACT GAC GGT GGG AGA AT-'3 
Reverse primer: 5'-CCC GGC AAA ACA GGT AGT TA-'3 
Validation of the micro array data  
Genes which showed expressional changes (P < 0.05 and fold change < 1.5) in PVAT of Rictor
aP2KO
 
mice were ranked in descending order. The 10 most increased and 10 most reduced genes were 
chosen for validation with quantitative RT-PCR (qRT-PCR). 
Briefly, control and Rictor
aP2KO
 mice were starved overnight and euthanized at 9 am (ZT 2). For 
tissue storage, RNA isolation and reverse transcription please refer to 2.1.10 (genome expression 
study). The procedure of the qRT-PCR was as followed: Gene expression was analyzed using 1x 
“iQ™ SYBR® Green Supermix” (Bio-Rad Laboratories GmbH, Munich, Germany), target gene 
specific mouse primer pairs (150 nM) and cDNA (10 ng) in a final volume of 20 µl. The qRT-PCR 
was performed as outlined in table A-1 using clear 96-well plates and the CFX96® qRT-PCR system 
(Bio-Rad Laboratories GmbH, Munich, Germany). Specifically designed mouse primer pairs used 
are listed in table A-2. Specificity of the qRT-PCR products was confirmed by analysis of the 
melting curve and agarose gel electrophoresis. Gene expression was calculated using the Δ(CT)-
method [329] and normalized to the housekeeping gene acidic ribosomal phosphoprotein PO 
(Arbp). Values are expressed as arbitrary units (AU). 
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Table A-1: Protocol for the quantitative RT-PCR used to validate micro array data.  
 
 Temperature (°C) Time (sec) 
Initial denaturation 95 180 
Denaturation 95 15  
Annealing and elongation 60* 45  
Final elongation 60 120  
   
Melting curve 
95 60 
65 60 
65 - 95 (+ 0.5 °C per step) 10 (per step) 
20 180 
* = for Dgat1 and Srebp-1c 61°C and 75 nM final concentration of primers  
Table A-2 Primer pairs used to validate micro array data with quantitative RT-PCR. Primer pairs were 
designed using «primer blast» program (NCBI, USA) and are specific to mouse cDNA.  
Gene name Forward Primer (5'-3') Reverse Primer (5'-3') 
Chac1 TAC GGC TCC CTA GTG TGG AA CAC TCG GCC AGG CAT CTT G 
Cyp51A1 GAG GCA ACT TGC TTT CCA CG TGG TGG ACT TTT CGC TCC AG 
Dgat1 AGA AGA GGA CGA GGT GCG A GAT GGC ACC TCA GAT CCC AGT AG 
Fasn GTG ATA GCC GGT ATG TCG GG TAG AGC CCA GCC TTC CAT CT 
Fdps TGT AGA ACT GCT CCA GGC TTT CTT CCA GAA GCA GAG CGT CG 
Fosb GAA AAG CGA AGG GTT CGC AG GCT GAT CAG TTT CCG CCT GA 
Gadd45b TGG TGA CGA ACC CAC ATT CA CGG GAG ATT AAT CAC GGG CA 
Glnd GGT GCC GAT TCG AGT GAT GA CTG ATC CAT TGT GGC CTG GT 
Irf4 TGT GAA AAT GGT TGC CAG GTG TGC TTG GCT CAA TGG GGA TT 
Mcpt4 CTG GAG CTG AGG AGA TTA TTG GT TGA ACC CTC TCT CAG TGG TG 
Ncan ATG GTG GCA CAT GAG AGT GG CCA CAC AGC ACT GTA CCC TT 
Nfil3 GAG CAG AAC CAC GAT AAC CCA T TAC AGA CCG GAT GGA GGA GAC 
Npas2 AGA GGC AGC TTG AAC CCA AA GAG GGG CTA GGC ACA TTG TT 
Nsdhl AGC TCT AGG TGG AAA GGC AT GTC AGA CGG GAC AGG AA 
Perilipin1 CCA TTG CAA GCA CCT CTG AC CCA CCT TCT CGA TGC TTC CC 
Rnu2 CTC GGC CTT TTG GCT AAG AT GGA GCA AGC TCC TAT TCC AA 
S100b TGC CCT CAT TGA TGT CTT CCA TGA TTT CCT CCA GGA AGT GAG AGA G 
Serpine1 TCC ACA AGT CTG ATG GCA GC GGG GTG GTG AAC TCA GTG TA 
Sesn2 CGC CAC TCA GAG AAG GTT CA ACG GGG TAG TCA GGT CAT GT 
Spry4 ACT CGG GTT CGG GGA TTT AC CAG GCT TCT AGG GGT CTT TGA 
Srebp-1c ATC GGC GCG GAA GCT GTC GGG GTA GCG TC ACT GTC TTG GTT GTT  GAT GAG CTG GAG CAT 
Thra AAG AAT GGT GGC TTG GGT G CGG AGC GGT CTG TTG ACA TTA 
Trdn GCC AAA CAC GCA AAC AGA AC GGA ACT TCT GGT GCT CCC TT 
 
  
Repeat 
 39 x 
Appendix 
115 
 
Fluctuating expression of Rictor and mTORC2 downstream targets in adipose tissue 
For tissue collection, RNA isolation, reverse transcription and qRT-PCR please refer to 2.1.10 (RNA 
isolation, reverse transcription and quantitative real-time PCR). Target gene specific mouse primer 
pairs were designed using “primer blast” (NCBI, USA) and are listed in table A-3. mRNA expression 
was analyzed over a 24 hour period. 
Table A-3: Primer pairs to analyze 24 hour mRNA expression patterns of indicated target genes in 
PVAT with quantitative RT-PCR. The «primer blast» program (NCBI, USA) was used to design primer 
pair’s specific to mouse cDNA.  
Gene 
name Forward Primer (5'-3') Reverse Primer (5'-3') 
Dbp GGA ACT GAA GCC TCA ACC AAT C CTC CGG CTC CAG TAC TTC TCA 
Nfil3 GAG CAG AAC CAC GAT AAC CCA T TAC AGA CCG GAT GGA GGA GAC 
Pgc-1α AGA TGA AGA GAA TGA GGC AAA C  GGC ATG GAG GAA GGA CTG 
Rictor TGC GAT ATT GGC CAT AGT GA ACC CGG CTG CTC TTA CTT CT 
Rorc CAT CAA TGC CAA CCG TCC TG CTT GGC TAG GAG GCC TTG TC 
Sirt-1 TGA GCT GAT GGA GGG GAT CA AGT TCC CAA TGC TGG TGG AG 
 
The expression and phosphorylation of the indicated target proteins was analyzed in EFAT and 
PVAT using Western Blot as follows: After euthanized, tissues were dissection from mice and 
tissue samples equilibrated for 30 min in DMEM without phenol red (Sigma-Aldrich, Buchs, 
Switzerland) at 37 °C and stimulated for additional 10 min with insulin (1 μmol/l). Tissues were 
snap frozen and kept at - 80 °C until further usage. Tissues were homogenized in tissue lysis buffer 
using Tissue Lyser (Qiagen, Hombrechtikon, Switzerland). 6 glass beads (3 mm) were used per 2 
ml safe-lock reaction tube. Tissue extracts were passed 4 times through a 20-G needle, 
centrifuged (10 min, 10000 x g, 4 °C) and the supernatant transferred to a new 1.5 ml reaction 
tube. Protein concentration was determined using Quick Start™ Bradford Protein Assay according 
manufactures recommendations. Protein working solutions were prepared as followed: protein 
lysate (2 µg/µl final concentration) and 2x sample buffer in a 50 µl volume. Samples were heated 
(95 °C, 5 min). Protein samples were loaded (22.5 µg protein) on a SDS-PAGE gel (table A-4), run 
(70 V for 20 min; 100 V for approx. 1 ¼ hours), transferred to a nitrocellulose membrane and 
analyzed using immune blot with their specific antibodies (table A-5). Membranes were incubated 
with the primary antibody overnight at 4 °C and with the secondary antibody at room 
temperature for 1 hour. Labelled proteins were visualized on x-ray films using a 
chemiluminescence reaction (SuperSignal West Pico or Femto, Life Technologies). ERK2 and total 
AKT were used as loading control. 
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(1) Tissue lysis buffer  
500 mM Tris (pH 7.5), 2 mM EDTA, 2 mM EGTA, 1 % Triton X, 10 % Glycerol, proteinase/ 
phosphatase inhibitor (Roche, Switzerland) 
(2) SDS-PAGE running buffer (1x) 
25 mM Tris-Base, 192 mM Glycine, 0,1 % SDS, pH 8.1 - 8.5 
(3) Transfer buffer (1x) 
25 mM Tris Base, 192 mM Glycine, 10 % Ethanol (absolute) 
(4) 2x SDS-PAGE sample buffer  
4 % SDS, 20 % glycerol, 120 mM Tris pH 6.8 and 5 % β-mercaptoethanol 
Table A-4 Composition and preparation of a SDS-PAGE gel 
Separating gel 8 %  Stacking Gel   3 % 
H2O 5.4 ml  H2O 3 ml 
Tris-HCl (1.5 M) pH 8.8 2.5 ml  Tris-HCl (1.0 M) pH 6.8 0.5 ml 
Acrylamide 29 % 2 ml  Acrylamide 29 % 0.46 ml 
SDS 10 % 1.0 ml  SDS 10 % 0.04 ml 
APS 10 % 0.1 ml  APS 10 % 0.04 ml 
Temed 0.01ml  Temed 0.005 ml 
 
Table A-5: Antibodies used in this study 
Antibody Catalog No. Company 
RICTOR # 2140 Cell signaling 
mTOR # 2983 Cell signaling 
Total AKT # 9272 Cell signaling 
phospho AKT Serine 473 # 3787 Cell signaling 
phospho AKT Threonine 308 # 4056 Cell signaling 
ERK 2 # sc-271451 Santa Cruz 
Amersham ECL Rabbit IgG, HRP-linked  
whole Ab (from donkey) 
# NA934-100UL Amersham 
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